US IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week_老虎社区_美港股上老虎

US IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week

Renaissance Capital2021-10-04

In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies. Fitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

971

GovinNandy
·2021-10-04
Aahaaan
回复
1
举报
Kel9670ong
·2021-10-04
Good to know and tbh these are all unknown corporation.
回复
1
举报
MorphyInc
·2021-10-04
Ifit ftw
回复
1
举报
WeiMin
·2021-10-04
Good to see that. Like!
回复
1
举报
Prosperity88
·2021-10-04
Qelllll
回复
4
举报
ming22
·2021-10-04
Good to know
回复
3
举报
LionCaleb
·2021-10-04
Strong
回复
3
举报
KH321
·2021-10-04
OK
回复
4
举报
Chanelyap
·2021-10-04
Like thanks
回复
8
举报
收起
- hello369:
  Done
  2021-10-04
  回复
  举报
- JeremyKok:
  hi. please like and comment back. thank you.
  2021-10-05
  回复
  举报
SilentWarrio
·2021-10-04
Is this a good time to buy? So much uncertainties...
回复
4
举报
收起
- ming22:
  Ya, have some concern too
  2021-10-04
  回复
  举报
beebeeyan
·2021-10-04
oh
回复
4
举报
Tamashii
·2021-10-04
Good luck
回复
5
举报
收起
- beebeeyan:
  oh
  2021-10-04
  回复
  举报
PEPESZ
·2021-10-04
Like pls, thx!
回复
5
举报
收起
- JeremyKok:
  hi. please like and comment back. thank you.
  2021-10-05
  回复
  举报
Deonc
·2021-10-04
New IPO.please like
回复
11
举报
收起
- Joe0319:
  ok
  2021-10-04
  回复
  举报
- Haw75:
  latest
  2021-10-04
  回复
  举报
- Deonc:
  thanks
  2021-10-04
  回复
  举报
查看更多 2 条评论
FrederickL
·2021-10-04
Like pls ! Thanks !
回复
9
举报
收起
- sugizoi4u:
  Done
  2021-10-04
  回复
  举报
- JeremyKok:
  hi. please like and comment back. thank you.
  2021-10-05
  回复
  举报
jimmylaw
·2021-10-04
Like comment
回复
7
举报
收起
- Chanelyap:
  Ok
  2021-10-04
  回复
  举报
CynthiaGho
·2021-10-04
Like pls
回复
6
举报
收起
- jimmylaw:
  comment like
  2021-10-04
  回复
  举报
- JeremyKok:
  hi. please like and comment back. thank you.
  2021-10-05
  回复
  举报
OddEyeCircle
·2021-10-04
Please like and comment
回复
8
举报
收起
- CynthiaGho:
  👍
  2021-10-04
  回复
  举报
- JeremyKok:
  hi. please like and comment back. thank you.
  2021-10-05
  回复
  举报
FlareSpark
·2021-10-04
New opportunities
回复
9
举报
收起
- p3aceboi:
  [Miser]
  2021-10-04
  回复
  举报
- OddEyeCircle:
  please like and comment
  2021-10-04
  回复
  举报
Nanamoney
·2021-10-04
This can be interesting. Thanks
回复
7
举报

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1186540865?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-10-04 03:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1186540865","market":"us","top_or_hot":-1,"title":"US IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week","media":"Renaissance Capital","content":"<div>\nIn the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.\nFitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion ...\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/86747/US-IPO-Week-Ahead-New-issuers-work-up-a-sweat-in-a-fitness-led-5-IPO-week\">网页链接</a>\n\n</div>\n","source":"lsy1603787993745","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-04 03:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/86747/US-IPO-Week-Ahead-New-issuers-work-up-a-sweat-in-a-fitness-led-5-IPO-week>Renaissance Capital</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nIn the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.\nFitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion ...\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/86747/US-IPO-Week-Ahead-New-issuers-work-up-a-sweat-in-a-fitness-led-5-IPO-week\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ISO","symbol_name":"IsoPlexis Corp.","start_time":0,"source_url":"https://www.renaissancecapital.com/IPO-Center/News/86747/US-IPO-Week-Ahead-New-issuers-work-up-a-sweat-in-a-fitness-led-5-IPO-week","article_id":"1186540865","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1186540865","pubTimestamp":1633289898,"columns":[],"sourceInfo":{"source_id":"lsy1603787993745","name":"Renaissance Capital"},"weMediaInfo":null,"summary":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness co","collect":0,"end_time":0,"defaultTopTitle":"renaissancecapital.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"ISO":"IsoPlexis Corp.","LTH":"Life Time Group Holdings, Inc.","THRX":"Theseus Pharmaceuticals, Inc.","CING":"CINGULATE INC."},"translate_title":"美国首次公开募股周：新发行人在健康导向的5周IPO中挥汗如雨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ISO":0.9,"IFIT":0.9,"CING":0.9,"THRX":0.9,"LTH":0.9},"content_text":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.\nFitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.\nFitness equipment brandiFIT Health & Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.\nProteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.\nBiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.\nDrug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[{"id":820928088,"gmtCreate":1633343699995,"gmtModify":1633343700109,"author":{"id":"4094370287156360","authorId":"4094370287156360","name":"GovinNandy","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"4094370287156360","authorIdStr":"4094370287156360"},"htmlText":"Aahaaan","listText":"Aahaaan","text":"Aahaaan","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/820928088","repostId":1186540865,"repostType":4,"repost":{"id":"1186540865","kind":"news","pubTimestamp":1633289898,"share":"https://www.laohu8.com/m/news/1186540865?lang=zh_CN&edition=full","pubTime":"2021-10-04 03:38","market":"us","language":"en","title":"US IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1186540865","media":"Renaissance Capital","summary":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness co","content":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.<blockquote>在10月的第一周，由两家健身公司牵头的五起IPO预计将筹集18亿美元。</blockquote> Fitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.<blockquote>健身连锁生命时代集团控股(LTH)计划以41亿美元的市值筹集9.01亿美元。Life Time于2015年私有化，在美国29个州和加拿大一个省运营着150多个“中心”，截至2011年7月31日，为近140万个人会员提供服务。尽管该公司受到疫情的严重打击，但此后运营情况显着改善，2021年第二季度的收入翻了两番。</blockquote> Fitness equipment brandiFIT Health &amp; Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.<blockquote>健身器材品牌iFIT健康与健身(IFIT)计划以64亿美元的市值筹集6亿美元。iFIT是美国排名第一的大型健身器材供应商，销售品牌包括iFIT、NordicTrack、ProForm和Freemotion。该公司发展迅速，但尚未盈利，为120多个国家的超过610万会员和150万订户提供服务。</blockquote> Proteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.<blockquote>蛋白质组学平台等丛(ISO)计划以6.48亿美元的市值筹集1.25亿美元。IsoPlexis认为其平台是第一个同时采用蛋白质组学和单细胞生物学来表征细胞功能并将其与患者结果联系起来的平台。自2018年6月商业推出以来，该公司的平台增长迅速且利润丰厚，已被全球15大生物制药公司和美国近一半的综合癌症中心采用。</blockquote> BiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.<blockquote>生物技术忒修斯制药公司(THRX)计划以5.93亿美元的市值筹集1.25亿美元。Theseus的主要候选药物是胃肠道间质瘤(GIST)KIT激酶所有主要激活/耐药突变类别的泛变体抑制剂。该公司最近提交了高级GIST的IND，并计划在2021年第四季度晚期和2022年第一季度中部之间启动1/2期试验。</blockquote> Drug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.<blockquote>药物开发人员扣带(CING)计划以2.25亿美元的市值筹集5000万美元。其两种候选药物CTx-1301和CTx-1302正在开发用于治疗ADHD。该公司于2020年10月宣布了CTX-1301 1/2期研究的积极结果，并计划在2021年第四季度启动3期试验，预计将于2022年底获得结果。</blockquote> <img src=\"https://static.tigerbbs.com/610fa042e4de459e4597ed8086743234\" tg-width=\"1894\" tg-height=\"912\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nRenaissance Capital2021-10-04 03:38\n\n</h4>\n</header>\n<article>\nIn the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.<blockquote>在10月的第一周，由两家健身公司牵头的五起IPO预计将筹集18亿美元。</blockquote> Fitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.<blockquote>健身连锁生命时代集团控股(LTH)计划以41亿美元的市值筹集9.01亿美元。Life Time于2015年私有化，在美国29个州和加拿大一个省运营着150多个“中心”，截至2011年7月31日，为近140万个人会员提供服务。尽管该公司受到疫情的严重打击，但此后运营情况显着改善，2021年第二季度的收入翻了两番。</blockquote> Fitness equipment brandiFIT Health &amp; Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.<blockquote>健身器材品牌iFIT健康与健身(IFIT)计划以64亿美元的市值筹集6亿美元。iFIT是美国排名第一的大型健身器材供应商，销售品牌包括iFIT、NordicTrack、ProForm和Freemotion。该公司发展迅速，但尚未盈利，为120多个国家的超过610万会员和150万订户提供服务。</blockquote> Proteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.<blockquote>蛋白质组学平台等丛(ISO)计划以6.48亿美元的市值筹集1.25亿美元。IsoPlexis认为其平台是第一个同时采用蛋白质组学和单细胞生物学来表征细胞功能并将其与患者结果联系起来的平台。自2018年6月商业推出以来，该公司的平台增长迅速且利润丰厚，已被全球15大生物制药公司和美国近一半的综合癌症中心采用。</blockquote> BiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.<blockquote>生物技术忒修斯制药公司(THRX)计划以5.93亿美元的市值筹集1.25亿美元。Theseus的主要候选药物是胃肠道间质瘤(GIST)KIT激酶所有主要激活/耐药突变类别的泛变体抑制剂。该公司最近提交了高级GIST的IND，并计划在2021年第四季度晚期和2022年第一季度中部之间启动1/2期试验。</blockquote> Drug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.<blockquote>药物开发人员扣带(CING)计划以2.25亿美元的市值筹集5000万美元。其两种候选药物CTx-1301和CTx-1302正在开发用于治疗ADHD。该公司于2020年10月宣布了CTX-1301 1/2期研究的积极结果，并计划在2021年第四季度启动3期试验，预计将于2022年底获得结果。</blockquote> <img src=\"https://static.tigerbbs.com/610fa042e4de459e4597ed8086743234\" tg-width=\"1894\" tg-height=\"912\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.renaissancecapital.com/IPO-Center/News/86747/US-IPO-Week-Ahead-New-issuers-work-up-a-sweat-in-a-fitness-led-5-IPO-week\">Renaissance Capital</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ISO":"IsoPlexis Corp.","LTH":"Life Time Group Holdings, Inc.","THRX":"Theseus Pharmaceuticals, Inc.","CING":"CINGULATE INC."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/86747/US-IPO-Week-Ahead-New-issuers-work-up-a-sweat-in-a-fitness-led-5-IPO-week","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186540865","content_text":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.\nFitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.\nFitness equipment brandiFIT Health & Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.\nProteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.\nBiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.\nDrug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.","news_type":1,"symbols_score_info":{"ISO":0.9,"IFIT":0.9,"CING":0.9,"THRX":0.9,"LTH":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":820918457,"gmtCreate":1633339402139,"gmtModify":1633339403112,"author":{"id":"3578468158955348","authorId":"3578468158955348","name":"Kel9670ong","avatar":"https://static.tigerbbs.com/bd86c42e207fbd94e7f8877a29457d71","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3578468158955348","authorIdStr":"3578468158955348"},"htmlText":"Good to know and tbh these are all unknown corporation.&nbsp;","listText":"Good to know and tbh these are all unknown corporation.&nbsp;","text":"Good to know and tbh these are all unknown corporation.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/820918457","repostId":1186540865,"repostType":4,"repost":{"id":"1186540865","kind":"news","pubTimestamp":1633289898,"share":"https://www.laohu8.com/m/news/1186540865?lang=zh_CN&edition=full","pubTime":"2021-10-04 03:38","market":"us","language":"en","title":"US IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1186540865","media":"Renaissance Capital","summary":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness co","content":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.<blockquote>在10月的第一周，由两家健身公司牵头的五起IPO预计将筹集18亿美元。</blockquote> Fitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.<blockquote>健身连锁生命时代集团控股(LTH)计划以41亿美元的市值筹集9.01亿美元。Life Time于2015年私有化，在美国29个州和加拿大一个省运营着150多个“中心”，截至2011年7月31日，为近140万个人会员提供服务。尽管该公司受到疫情的严重打击，但此后运营情况显着改善，2021年第二季度的收入翻了两番。</blockquote> Fitness equipment brandiFIT Health &amp; Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.<blockquote>健身器材品牌iFIT健康与健身(IFIT)计划以64亿美元的市值筹集6亿美元。iFIT是美国排名第一的大型健身器材供应商，销售品牌包括iFIT、NordicTrack、ProForm和Freemotion。该公司发展迅速，但尚未盈利，为120多个国家的超过610万会员和150万订户提供服务。</blockquote> Proteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.<blockquote>蛋白质组学平台等丛(ISO)计划以6.48亿美元的市值筹集1.25亿美元。IsoPlexis认为其平台是第一个同时采用蛋白质组学和单细胞生物学来表征细胞功能并将其与患者结果联系起来的平台。自2018年6月商业推出以来，该公司的平台增长迅速且利润丰厚，已被全球15大生物制药公司和美国近一半的综合癌症中心采用。</blockquote> BiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.<blockquote>生物技术忒修斯制药公司(THRX)计划以5.93亿美元的市值筹集1.25亿美元。Theseus的主要候选药物是胃肠道间质瘤(GIST)KIT激酶所有主要激活/耐药突变类别的泛变体抑制剂。该公司最近提交了高级GIST的IND，并计划在2021年第四季度晚期和2022年第一季度中部之间启动1/2期试验。</blockquote> Drug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.<blockquote>药物开发人员扣带(CING)计划以2.25亿美元的市值筹集5000万美元。其两种候选药物CTx-1301和CTx-1302正在开发用于治疗ADHD。该公司于2020年10月宣布了CTX-1301 1/2期研究的积极结果，并计划在2021年第四季度启动3期试验，预计将于2022年底获得结果。</blockquote> <img src=\"https://static.tigerbbs.com/610fa042e4de459e4597ed8086743234\" tg-width=\"1894\" tg-height=\"912\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nRenaissance Capital2021-10-04 03:38\n\n</h4>\n</header>\n<article>\nIn the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.<blockquote>在10月的第一周，由两家健身公司牵头的五起IPO预计将筹集18亿美元。</blockquote> Fitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.<blockquote>健身连锁生命时代集团控股(LTH)计划以41亿美元的市值筹集9.01亿美元。Life Time于2015年私有化，在美国29个州和加拿大一个省运营着150多个“中心”，截至2011年7月31日，为近140万个人会员提供服务。尽管该公司受到疫情的严重打击，但此后运营情况显着改善，2021年第二季度的收入翻了两番。</blockquote> Fitness equipment brandiFIT Health &amp; Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.<blockquote>健身器材品牌iFIT健康与健身(IFIT)计划以64亿美元的市值筹集6亿美元。iFIT是美国排名第一的大型健身器材供应商，销售品牌包括iFIT、NordicTrack、ProForm和Freemotion。该公司发展迅速，但尚未盈利，为120多个国家的超过610万会员和150万订户提供服务。</blockquote> Proteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.<blockquote>蛋白质组学平台等丛(ISO)计划以6.48亿美元的市值筹集1.25亿美元。IsoPlexis认为其平台是第一个同时采用蛋白质组学和单细胞生物学来表征细胞功能并将其与患者结果联系起来的平台。自2018年6月商业推出以来，该公司的平台增长迅速且利润丰厚，已被全球15大生物制药公司和美国近一半的综合癌症中心采用。</blockquote> BiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.<blockquote>生物技术忒修斯制药公司(THRX)计划以5.93亿美元的市值筹集1.25亿美元。Theseus的主要候选药物是胃肠道间质瘤(GIST)KIT激酶所有主要激活/耐药突变类别的泛变体抑制剂。该公司最近提交了高级GIST的IND，并计划在2021年第四季度晚期和2022年第一季度中部之间启动1/2期试验。</blockquote> Drug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.<blockquote>药物开发人员扣带(CING)计划以2.25亿美元的市值筹集5000万美元。其两种候选药物CTx-1301和CTx-1302正在开发用于治疗ADHD。该公司于2020年10月宣布了CTX-1301 1/2期研究的积极结果，并计划在2021年第四季度启动3期试验，预计将于2022年底获得结果。</blockquote> <img src=\"https://static.tigerbbs.com/610fa042e4de459e4597ed8086743234\" tg-width=\"1894\" tg-height=\"912\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.renaissancecapital.com/IPO-Center/News/86747/US-IPO-Week-Ahead-New-issuers-work-up-a-sweat-in-a-fitness-led-5-IPO-week\">Renaissance Capital</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ISO":"IsoPlexis Corp.","LTH":"Life Time Group Holdings, Inc.","THRX":"Theseus Pharmaceuticals, Inc.","CING":"CINGULATE INC."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/86747/US-IPO-Week-Ahead-New-issuers-work-up-a-sweat-in-a-fitness-led-5-IPO-week","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186540865","content_text":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.\nFitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.\nFitness equipment brandiFIT Health & Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.\nProteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.\nBiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.\nDrug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.","news_type":1,"symbols_score_info":{"ISO":0.9,"IFIT":0.9,"CING":0.9,"THRX":0.9,"LTH":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":820047557,"gmtCreate":1633332600719,"gmtModify":1633332601211,"author":{"id":"3575256884333459","authorId":"3575256884333459","name":"MorphyInc","avatar":"https://static.tigerbbs.com/8fa62407baa49ccbcbca7d374aa8a803","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3575256884333459","authorIdStr":"3575256884333459"},"htmlText":"Ifit ftw","listText":"Ifit ftw","text":"Ifit ftw","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/820047557","repostId":1186540865,"repostType":4,"repost":{"id":"1186540865","kind":"news","pubTimestamp":1633289898,"share":"https://www.laohu8.com/m/news/1186540865?lang=zh_CN&edition=full","pubTime":"2021-10-04 03:38","market":"us","language":"en","title":"US IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1186540865","media":"Renaissance Capital","summary":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness co","content":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.<blockquote>在10月的第一周，由两家健身公司牵头的五起IPO预计将筹集18亿美元。</blockquote> Fitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.<blockquote>健身连锁生命时代集团控股(LTH)计划以41亿美元的市值筹集9.01亿美元。Life Time于2015年私有化，在美国29个州和加拿大一个省运营着150多个“中心”，截至2011年7月31日，为近140万个人会员提供服务。尽管该公司受到疫情的严重打击，但此后运营情况显着改善，2021年第二季度的收入翻了两番。</blockquote> Fitness equipment brandiFIT Health &amp; Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.<blockquote>健身器材品牌iFIT健康与健身(IFIT)计划以64亿美元的市值筹集6亿美元。iFIT是美国排名第一的大型健身器材供应商，销售品牌包括iFIT、NordicTrack、ProForm和Freemotion。该公司发展迅速，但尚未盈利，为120多个国家的超过610万会员和150万订户提供服务。</blockquote> Proteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.<blockquote>蛋白质组学平台等丛(ISO)计划以6.48亿美元的市值筹集1.25亿美元。IsoPlexis认为其平台是第一个同时采用蛋白质组学和单细胞生物学来表征细胞功能并将其与患者结果联系起来的平台。自2018年6月商业推出以来，该公司的平台增长迅速且利润丰厚，已被全球15大生物制药公司和美国近一半的综合癌症中心采用。</blockquote> BiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.<blockquote>生物技术忒修斯制药公司(THRX)计划以5.93亿美元的市值筹集1.25亿美元。Theseus的主要候选药物是胃肠道间质瘤(GIST)KIT激酶所有主要激活/耐药突变类别的泛变体抑制剂。该公司最近提交了高级GIST的IND，并计划在2021年第四季度晚期和2022年第一季度中部之间启动1/2期试验。</blockquote> Drug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.<blockquote>药物开发人员扣带(CING)计划以2.25亿美元的市值筹集5000万美元。其两种候选药物CTx-1301和CTx-1302正在开发用于治疗ADHD。该公司于2020年10月宣布了CTX-1301 1/2期研究的积极结果，并计划在2021年第四季度启动3期试验，预计将于2022年底获得结果。</blockquote> <img src=\"https://static.tigerbbs.com/610fa042e4de459e4597ed8086743234\" tg-width=\"1894\" tg-height=\"912\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nRenaissance Capital2021-10-04 03:38\n\n</h4>\n</header>\n<article>\nIn the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.<blockquote>在10月的第一周，由两家健身公司牵头的五起IPO预计将筹集18亿美元。</blockquote> Fitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.<blockquote>健身连锁生命时代集团控股(LTH)计划以41亿美元的市值筹集9.01亿美元。Life Time于2015年私有化，在美国29个州和加拿大一个省运营着150多个“中心”，截至2011年7月31日，为近140万个人会员提供服务。尽管该公司受到疫情的严重打击，但此后运营情况显着改善，2021年第二季度的收入翻了两番。</blockquote> Fitness equipment brandiFIT Health &amp; Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.<blockquote>健身器材品牌iFIT健康与健身(IFIT)计划以64亿美元的市值筹集6亿美元。iFIT是美国排名第一的大型健身器材供应商，销售品牌包括iFIT、NordicTrack、ProForm和Freemotion。该公司发展迅速，但尚未盈利，为120多个国家的超过610万会员和150万订户提供服务。</blockquote> Proteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.<blockquote>蛋白质组学平台等丛(ISO)计划以6.48亿美元的市值筹集1.25亿美元。IsoPlexis认为其平台是第一个同时采用蛋白质组学和单细胞生物学来表征细胞功能并将其与患者结果联系起来的平台。自2018年6月商业推出以来，该公司的平台增长迅速且利润丰厚，已被全球15大生物制药公司和美国近一半的综合癌症中心采用。</blockquote> BiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.<blockquote>生物技术忒修斯制药公司(THRX)计划以5.93亿美元的市值筹集1.25亿美元。Theseus的主要候选药物是胃肠道间质瘤(GIST)KIT激酶所有主要激活/耐药突变类别的泛变体抑制剂。该公司最近提交了高级GIST的IND，并计划在2021年第四季度晚期和2022年第一季度中部之间启动1/2期试验。</blockquote> Drug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.<blockquote>药物开发人员扣带(CING)计划以2.25亿美元的市值筹集5000万美元。其两种候选药物CTx-1301和CTx-1302正在开发用于治疗ADHD。该公司于2020年10月宣布了CTX-1301 1/2期研究的积极结果，并计划在2021年第四季度启动3期试验，预计将于2022年底获得结果。</blockquote> <img src=\"https://static.tigerbbs.com/610fa042e4de459e4597ed8086743234\" tg-width=\"1894\" tg-height=\"912\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.renaissancecapital.com/IPO-Center/News/86747/US-IPO-Week-Ahead-New-issuers-work-up-a-sweat-in-a-fitness-led-5-IPO-week\">Renaissance Capital</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ISO":"IsoPlexis Corp.","LTH":"Life Time Group Holdings, Inc.","THRX":"Theseus Pharmaceuticals, Inc.","CING":"CINGULATE INC."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/86747/US-IPO-Week-Ahead-New-issuers-work-up-a-sweat-in-a-fitness-led-5-IPO-week","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186540865","content_text":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.\nFitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.\nFitness equipment brandiFIT Health & Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.\nProteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.\nBiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.\nDrug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.","news_type":1,"symbols_score_info":{"ISO":0.9,"IFIT":0.9,"CING":0.9,"THRX":0.9,"LTH":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":820054723,"gmtCreate":1633330783588,"gmtModify":1633330783917,"author":{"id":"3562741582743244","authorId":"3562741582743244","name":"WeiMin","avatar":"https://static.tigerbbs.com/5716e0600a0772002dec70de6433291d","vip":1,"crmLevel":9,"crmLevelSwitch":0,"idStr":"3562741582743244","authorIdStr":"3562741582743244"},"htmlText":"Good to see that. Like!","listText":"Good to see that. Like!","text":"Good to see that. Like!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/820054723","repostId":1186540865,"repostType":4,"repost":{"id":"1186540865","kind":"news","pubTimestamp":1633289898,"share":"https://www.laohu8.com/m/news/1186540865?lang=zh_CN&edition=full","pubTime":"2021-10-04 03:38","market":"us","language":"en","title":"US IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1186540865","media":"Renaissance Capital","summary":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness co","content":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.<blockquote>在10月的第一周，由两家健身公司牵头的五起IPO预计将筹集18亿美元。</blockquote> Fitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.<blockquote>健身连锁生命时代集团控股(LTH)计划以41亿美元的市值筹集9.01亿美元。Life Time于2015年私有化，在美国29个州和加拿大一个省运营着150多个“中心”，截至2011年7月31日，为近140万个人会员提供服务。尽管该公司受到疫情的严重打击，但此后运营情况显着改善，2021年第二季度的收入翻了两番。</blockquote> Fitness equipment brandiFIT Health &amp; Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.<blockquote>健身器材品牌iFIT健康与健身(IFIT)计划以64亿美元的市值筹集6亿美元。iFIT是美国排名第一的大型健身器材供应商，销售品牌包括iFIT、NordicTrack、ProForm和Freemotion。该公司发展迅速，但尚未盈利，为120多个国家的超过610万会员和150万订户提供服务。</blockquote> Proteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.<blockquote>蛋白质组学平台等丛(ISO)计划以6.48亿美元的市值筹集1.25亿美元。IsoPlexis认为其平台是第一个同时采用蛋白质组学和单细胞生物学来表征细胞功能并将其与患者结果联系起来的平台。自2018年6月商业推出以来，该公司的平台增长迅速且利润丰厚，已被全球15大生物制药公司和美国近一半的综合癌症中心采用。</blockquote> BiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.<blockquote>生物技术忒修斯制药公司(THRX)计划以5.93亿美元的市值筹集1.25亿美元。Theseus的主要候选药物是胃肠道间质瘤(GIST)KIT激酶所有主要激活/耐药突变类别的泛变体抑制剂。该公司最近提交了高级GIST的IND，并计划在2021年第四季度晚期和2022年第一季度中部之间启动1/2期试验。</blockquote> Drug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.<blockquote>药物开发人员扣带(CING)计划以2.25亿美元的市值筹集5000万美元。其两种候选药物CTx-1301和CTx-1302正在开发用于治疗ADHD。该公司于2020年10月宣布了CTX-1301 1/2期研究的积极结果，并计划在2021年第四季度启动3期试验，预计将于2022年底获得结果。</blockquote> <img src=\"https://static.tigerbbs.com/610fa042e4de459e4597ed8086743234\" tg-width=\"1894\" tg-height=\"912\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nRenaissance Capital2021-10-04 03:38\n\n</h4>\n</header>\n<article>\nIn the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.<blockquote>在10月的第一周，由两家健身公司牵头的五起IPO预计将筹集18亿美元。</blockquote> Fitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.<blockquote>健身连锁生命时代集团控股(LTH)计划以41亿美元的市值筹集9.01亿美元。Life Time于2015年私有化，在美国29个州和加拿大一个省运营着150多个“中心”，截至2011年7月31日，为近140万个人会员提供服务。尽管该公司受到疫情的严重打击，但此后运营情况显着改善，2021年第二季度的收入翻了两番。</blockquote> Fitness equipment brandiFIT Health &amp; Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.<blockquote>健身器材品牌iFIT健康与健身(IFIT)计划以64亿美元的市值筹集6亿美元。iFIT是美国排名第一的大型健身器材供应商，销售品牌包括iFIT、NordicTrack、ProForm和Freemotion。该公司发展迅速，但尚未盈利，为120多个国家的超过610万会员和150万订户提供服务。</blockquote> Proteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.<blockquote>蛋白质组学平台等丛(ISO)计划以6.48亿美元的市值筹集1.25亿美元。IsoPlexis认为其平台是第一个同时采用蛋白质组学和单细胞生物学来表征细胞功能并将其与患者结果联系起来的平台。自2018年6月商业推出以来，该公司的平台增长迅速且利润丰厚，已被全球15大生物制药公司和美国近一半的综合癌症中心采用。</blockquote> BiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.<blockquote>生物技术忒修斯制药公司(THRX)计划以5.93亿美元的市值筹集1.25亿美元。Theseus的主要候选药物是胃肠道间质瘤(GIST)KIT激酶所有主要激活/耐药突变类别的泛变体抑制剂。该公司最近提交了高级GIST的IND，并计划在2021年第四季度晚期和2022年第一季度中部之间启动1/2期试验。</blockquote> Drug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.<blockquote>药物开发人员扣带(CING)计划以2.25亿美元的市值筹集5000万美元。其两种候选药物CTx-1301和CTx-1302正在开发用于治疗ADHD。该公司于2020年10月宣布了CTX-1301 1/2期研究的积极结果，并计划在2021年第四季度启动3期试验，预计将于2022年底获得结果。</blockquote> <img src=\"https://static.tigerbbs.com/610fa042e4de459e4597ed8086743234\" tg-width=\"1894\" tg-height=\"912\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.renaissancecapital.com/IPO-Center/News/86747/US-IPO-Week-Ahead-New-issuers-work-up-a-sweat-in-a-fitness-led-5-IPO-week\">Renaissance Capital</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ISO":"IsoPlexis Corp.","LTH":"Life Time Group Holdings, Inc.","THRX":"Theseus Pharmaceuticals, Inc.","CING":"CINGULATE INC."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/86747/US-IPO-Week-Ahead-New-issuers-work-up-a-sweat-in-a-fitness-led-5-IPO-week","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186540865","content_text":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.\nFitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.\nFitness equipment brandiFIT Health & Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.\nProteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.\nBiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.\nDrug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.","news_type":1,"symbols_score_info":{"ISO":0.9,"IFIT":0.9,"CING":0.9,"THRX":0.9,"LTH":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":820081844,"gmtCreate":1633325263613,"gmtModify":1633325264214,"author":{"id":"3569644599778803","authorId":"3569644599778803","name":"Prosperity88","avatar":"https://static.tigerbbs.com/673e75041219828ee5fce0d5b00ebbfe","vip":1,"crmLevel":12,"crmLevelSwitch":0,"idStr":"3569644599778803","authorIdStr":"3569644599778803"},"htmlText":"Qelllll","listText":"Qelllll","text":"Qelllll","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/820081844","repostId":1186540865,"repostType":4,"repost":{"id":"1186540865","kind":"news","pubTimestamp":1633289898,"share":"https://www.laohu8.com/m/news/1186540865?lang=zh_CN&edition=full","pubTime":"2021-10-04 03:38","market":"us","language":"en","title":"US IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1186540865","media":"Renaissance Capital","summary":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness co","content":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.<blockquote>在10月的第一周，由两家健身公司牵头的五起IPO预计将筹集18亿美元。</blockquote> Fitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.<blockquote>健身连锁生命时代集团控股(LTH)计划以41亿美元的市值筹集9.01亿美元。Life Time于2015年私有化，在美国29个州和加拿大一个省运营着150多个“中心”，截至2011年7月31日，为近140万个人会员提供服务。尽管该公司受到疫情的严重打击，但此后运营情况显着改善，2021年第二季度的收入翻了两番。</blockquote> Fitness equipment brandiFIT Health &amp; Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.<blockquote>健身器材品牌iFIT健康与健身(IFIT)计划以64亿美元的市值筹集6亿美元。iFIT是美国排名第一的大型健身器材供应商，销售品牌包括iFIT、NordicTrack、ProForm和Freemotion。该公司发展迅速，但尚未盈利，为120多个国家的超过610万会员和150万订户提供服务。</blockquote> Proteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.<blockquote>蛋白质组学平台等丛(ISO)计划以6.48亿美元的市值筹集1.25亿美元。IsoPlexis认为其平台是第一个同时采用蛋白质组学和单细胞生物学来表征细胞功能并将其与患者结果联系起来的平台。自2018年6月商业推出以来，该公司的平台增长迅速且利润丰厚，已被全球15大生物制药公司和美国近一半的综合癌症中心采用。</blockquote> BiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.<blockquote>生物技术忒修斯制药公司(THRX)计划以5.93亿美元的市值筹集1.25亿美元。Theseus的主要候选药物是胃肠道间质瘤(GIST)KIT激酶所有主要激活/耐药突变类别的泛变体抑制剂。该公司最近提交了高级GIST的IND，并计划在2021年第四季度晚期和2022年第一季度中部之间启动1/2期试验。</blockquote> Drug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.<blockquote>药物开发人员扣带(CING)计划以2.25亿美元的市值筹集5000万美元。其两种候选药物CTx-1301和CTx-1302正在开发用于治疗ADHD。该公司于2020年10月宣布了CTX-1301 1/2期研究的积极结果，并计划在2021年第四季度启动3期试验，预计将于2022年底获得结果。</blockquote> <img src=\"https://static.tigerbbs.com/610fa042e4de459e4597ed8086743234\" tg-width=\"1894\" tg-height=\"912\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nRenaissance Capital2021-10-04 03:38\n\n</h4>\n</header>\n<article>\nIn the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.<blockquote>在10月的第一周，由两家健身公司牵头的五起IPO预计将筹集18亿美元。</blockquote> Fitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.<blockquote>健身连锁生命时代集团控股(LTH)计划以41亿美元的市值筹集9.01亿美元。Life Time于2015年私有化，在美国29个州和加拿大一个省运营着150多个“中心”，截至2011年7月31日，为近140万个人会员提供服务。尽管该公司受到疫情的严重打击，但此后运营情况显着改善，2021年第二季度的收入翻了两番。</blockquote> Fitness equipment brandiFIT Health &amp; Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.<blockquote>健身器材品牌iFIT健康与健身(IFIT)计划以64亿美元的市值筹集6亿美元。iFIT是美国排名第一的大型健身器材供应商，销售品牌包括iFIT、NordicTrack、ProForm和Freemotion。该公司发展迅速，但尚未盈利，为120多个国家的超过610万会员和150万订户提供服务。</blockquote> Proteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.<blockquote>蛋白质组学平台等丛(ISO)计划以6.48亿美元的市值筹集1.25亿美元。IsoPlexis认为其平台是第一个同时采用蛋白质组学和单细胞生物学来表征细胞功能并将其与患者结果联系起来的平台。自2018年6月商业推出以来，该公司的平台增长迅速且利润丰厚，已被全球15大生物制药公司和美国近一半的综合癌症中心采用。</blockquote> BiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.<blockquote>生物技术忒修斯制药公司(THRX)计划以5.93亿美元的市值筹集1.25亿美元。Theseus的主要候选药物是胃肠道间质瘤(GIST)KIT激酶所有主要激活/耐药突变类别的泛变体抑制剂。该公司最近提交了高级GIST的IND，并计划在2021年第四季度晚期和2022年第一季度中部之间启动1/2期试验。</blockquote> Drug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.<blockquote>药物开发人员扣带(CING)计划以2.25亿美元的市值筹集5000万美元。其两种候选药物CTx-1301和CTx-1302正在开发用于治疗ADHD。该公司于2020年10月宣布了CTX-1301 1/2期研究的积极结果，并计划在2021年第四季度启动3期试验，预计将于2022年底获得结果。</blockquote> <img src=\"https://static.tigerbbs.com/610fa042e4de459e4597ed8086743234\" tg-width=\"1894\" tg-height=\"912\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.renaissancecapital.com/IPO-Center/News/86747/US-IPO-Week-Ahead-New-issuers-work-up-a-sweat-in-a-fitness-led-5-IPO-week\">Renaissance Capital</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ISO":"IsoPlexis Corp.","LTH":"Life Time Group Holdings, Inc.","THRX":"Theseus Pharmaceuticals, Inc.","CING":"CINGULATE INC."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/86747/US-IPO-Week-Ahead-New-issuers-work-up-a-sweat-in-a-fitness-led-5-IPO-week","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186540865","content_text":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.\nFitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.\nFitness equipment brandiFIT Health & Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.\nProteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.\nBiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.\nDrug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.","news_type":1,"symbols_score_info":{"ISO":0.9,"IFIT":0.9,"CING":0.9,"THRX":0.9,"LTH":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":820083530,"gmtCreate":1633325158648,"gmtModify":1633325159576,"author":{"id":"3571044771112848","authorId":"3571044771112848","name":"ming22","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3571044771112848","authorIdStr":"3571044771112848"},"htmlText":"Good to know&nbsp;","listText":"Good to know&nbsp;","text":"Good to know","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/820083530","repostId":1186540865,"repostType":4,"repost":{"id":"1186540865","kind":"news","pubTimestamp":1633289898,"share":"https://www.laohu8.com/m/news/1186540865?lang=zh_CN&edition=full","pubTime":"2021-10-04 03:38","market":"us","language":"en","title":"US IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1186540865","media":"Renaissance Capital","summary":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness co","content":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.<blockquote>在10月的第一周，由两家健身公司牵头的五起IPO预计将筹集18亿美元。</blockquote> Fitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.<blockquote>健身连锁生命时代集团控股(LTH)计划以41亿美元的市值筹集9.01亿美元。Life Time于2015年私有化，在美国29个州和加拿大一个省运营着150多个“中心”，截至2011年7月31日，为近140万个人会员提供服务。尽管该公司受到疫情的严重打击，但此后运营情况显着改善，2021年第二季度的收入翻了两番。</blockquote> Fitness equipment brandiFIT Health &amp; Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.<blockquote>健身器材品牌iFIT健康与健身(IFIT)计划以64亿美元的市值筹集6亿美元。iFIT是美国排名第一的大型健身器材供应商，销售品牌包括iFIT、NordicTrack、ProForm和Freemotion。该公司发展迅速，但尚未盈利，为120多个国家的超过610万会员和150万订户提供服务。</blockquote> Proteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.<blockquote>蛋白质组学平台等丛(ISO)计划以6.48亿美元的市值筹集1.25亿美元。IsoPlexis认为其平台是第一个同时采用蛋白质组学和单细胞生物学来表征细胞功能并将其与患者结果联系起来的平台。自2018年6月商业推出以来，该公司的平台增长迅速且利润丰厚，已被全球15大生物制药公司和美国近一半的综合癌症中心采用。</blockquote> BiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.<blockquote>生物技术忒修斯制药公司(THRX)计划以5.93亿美元的市值筹集1.25亿美元。Theseus的主要候选药物是胃肠道间质瘤(GIST)KIT激酶所有主要激活/耐药突变类别的泛变体抑制剂。该公司最近提交了高级GIST的IND，并计划在2021年第四季度晚期和2022年第一季度中部之间启动1/2期试验。</blockquote> Drug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.<blockquote>药物开发人员扣带(CING)计划以2.25亿美元的市值筹集5000万美元。其两种候选药物CTx-1301和CTx-1302正在开发用于治疗ADHD。该公司于2020年10月宣布了CTX-1301 1/2期研究的积极结果，并计划在2021年第四季度启动3期试验，预计将于2022年底获得结果。</blockquote> <img src=\"https://static.tigerbbs.com/610fa042e4de459e4597ed8086743234\" tg-width=\"1894\" tg-height=\"912\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nRenaissance Capital2021-10-04 03:38\n\n</h4>\n</header>\n<article>\nIn the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.<blockquote>在10月的第一周，由两家健身公司牵头的五起IPO预计将筹集18亿美元。</blockquote> Fitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.<blockquote>健身连锁生命时代集团控股(LTH)计划以41亿美元的市值筹集9.01亿美元。Life Time于2015年私有化，在美国29个州和加拿大一个省运营着150多个“中心”，截至2011年7月31日，为近140万个人会员提供服务。尽管该公司受到疫情的严重打击，但此后运营情况显着改善，2021年第二季度的收入翻了两番。</blockquote> Fitness equipment brandiFIT Health &amp; Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.<blockquote>健身器材品牌iFIT健康与健身(IFIT)计划以64亿美元的市值筹集6亿美元。iFIT是美国排名第一的大型健身器材供应商，销售品牌包括iFIT、NordicTrack、ProForm和Freemotion。该公司发展迅速，但尚未盈利，为120多个国家的超过610万会员和150万订户提供服务。</blockquote> Proteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.<blockquote>蛋白质组学平台等丛(ISO)计划以6.48亿美元的市值筹集1.25亿美元。IsoPlexis认为其平台是第一个同时采用蛋白质组学和单细胞生物学来表征细胞功能并将其与患者结果联系起来的平台。自2018年6月商业推出以来，该公司的平台增长迅速且利润丰厚，已被全球15大生物制药公司和美国近一半的综合癌症中心采用。</blockquote> BiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.<blockquote>生物技术忒修斯制药公司(THRX)计划以5.93亿美元的市值筹集1.25亿美元。Theseus的主要候选药物是胃肠道间质瘤(GIST)KIT激酶所有主要激活/耐药突变类别的泛变体抑制剂。该公司最近提交了高级GIST的IND，并计划在2021年第四季度晚期和2022年第一季度中部之间启动1/2期试验。</blockquote> Drug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.<blockquote>药物开发人员扣带(CING)计划以2.25亿美元的市值筹集5000万美元。其两种候选药物CTx-1301和CTx-1302正在开发用于治疗ADHD。该公司于2020年10月宣布了CTX-1301 1/2期研究的积极结果，并计划在2021年第四季度启动3期试验，预计将于2022年底获得结果。</blockquote> <img src=\"https://static.tigerbbs.com/610fa042e4de459e4597ed8086743234\" tg-width=\"1894\" tg-height=\"912\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.renaissancecapital.com/IPO-Center/News/86747/US-IPO-Week-Ahead-New-issuers-work-up-a-sweat-in-a-fitness-led-5-IPO-week\">Renaissance Capital</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ISO":"IsoPlexis Corp.","LTH":"Life Time Group Holdings, Inc.","THRX":"Theseus Pharmaceuticals, Inc.","CING":"CINGULATE INC."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/86747/US-IPO-Week-Ahead-New-issuers-work-up-a-sweat-in-a-fitness-led-5-IPO-week","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186540865","content_text":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.\nFitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.\nFitness equipment brandiFIT Health & Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.\nProteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.\nBiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.\nDrug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.","news_type":1,"symbols_score_info":{"ISO":0.9,"IFIT":0.9,"CING":0.9,"THRX":0.9,"LTH":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":820034985,"gmtCreate":1633323229114,"gmtModify":1633323229343,"author":{"id":"3575603660958830","authorId":"3575603660958830","name":"LionCaleb","avatar":"https://static.tigerbbs.com/cd1f09c16d128eda9b88de93cde62337","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3575603660958830","authorIdStr":"3575603660958830"},"htmlText":"Strong","listText":"Strong","text":"Strong","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/820034985","repostId":1186540865,"repostType":4,"repost":{"id":"1186540865","kind":"news","pubTimestamp":1633289898,"share":"https://www.laohu8.com/m/news/1186540865?lang=zh_CN&edition=full","pubTime":"2021-10-04 03:38","market":"us","language":"en","title":"US IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1186540865","media":"Renaissance Capital","summary":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness co","content":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.<blockquote>在10月的第一周，由两家健身公司牵头的五起IPO预计将筹集18亿美元。</blockquote> Fitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.<blockquote>健身连锁生命时代集团控股(LTH)计划以41亿美元的市值筹集9.01亿美元。Life Time于2015年私有化，在美国29个州和加拿大一个省运营着150多个“中心”，截至2011年7月31日，为近140万个人会员提供服务。尽管该公司受到疫情的严重打击，但此后运营情况显着改善，2021年第二季度的收入翻了两番。</blockquote> Fitness equipment brandiFIT Health &amp; Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.<blockquote>健身器材品牌iFIT健康与健身(IFIT)计划以64亿美元的市值筹集6亿美元。iFIT是美国排名第一的大型健身器材供应商，销售品牌包括iFIT、NordicTrack、ProForm和Freemotion。该公司发展迅速，但尚未盈利，为120多个国家的超过610万会员和150万订户提供服务。</blockquote> Proteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.<blockquote>蛋白质组学平台等丛(ISO)计划以6.48亿美元的市值筹集1.25亿美元。IsoPlexis认为其平台是第一个同时采用蛋白质组学和单细胞生物学来表征细胞功能并将其与患者结果联系起来的平台。自2018年6月商业推出以来，该公司的平台增长迅速且利润丰厚，已被全球15大生物制药公司和美国近一半的综合癌症中心采用。</blockquote> BiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.<blockquote>生物技术忒修斯制药公司(THRX)计划以5.93亿美元的市值筹集1.25亿美元。Theseus的主要候选药物是胃肠道间质瘤(GIST)KIT激酶所有主要激活/耐药突变类别的泛变体抑制剂。该公司最近提交了高级GIST的IND，并计划在2021年第四季度晚期和2022年第一季度中部之间启动1/2期试验。</blockquote> Drug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.<blockquote>药物开发人员扣带(CING)计划以2.25亿美元的市值筹集5000万美元。其两种候选药物CTx-1301和CTx-1302正在开发用于治疗ADHD。该公司于2020年10月宣布了CTX-1301 1/2期研究的积极结果，并计划在2021年第四季度启动3期试验，预计将于2022年底获得结果。</blockquote> <img src=\"https://static.tigerbbs.com/610fa042e4de459e4597ed8086743234\" tg-width=\"1894\" tg-height=\"912\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nRenaissance Capital2021-10-04 03:38\n\n</h4>\n</header>\n<article>\nIn the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.<blockquote>在10月的第一周，由两家健身公司牵头的五起IPO预计将筹集18亿美元。</blockquote> Fitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.<blockquote>健身连锁生命时代集团控股(LTH)计划以41亿美元的市值筹集9.01亿美元。Life Time于2015年私有化，在美国29个州和加拿大一个省运营着150多个“中心”，截至2011年7月31日，为近140万个人会员提供服务。尽管该公司受到疫情的严重打击，但此后运营情况显着改善，2021年第二季度的收入翻了两番。</blockquote> Fitness equipment brandiFIT Health &amp; Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.<blockquote>健身器材品牌iFIT健康与健身(IFIT)计划以64亿美元的市值筹集6亿美元。iFIT是美国排名第一的大型健身器材供应商，销售品牌包括iFIT、NordicTrack、ProForm和Freemotion。该公司发展迅速，但尚未盈利，为120多个国家的超过610万会员和150万订户提供服务。</blockquote> Proteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.<blockquote>蛋白质组学平台等丛(ISO)计划以6.48亿美元的市值筹集1.25亿美元。IsoPlexis认为其平台是第一个同时采用蛋白质组学和单细胞生物学来表征细胞功能并将其与患者结果联系起来的平台。自2018年6月商业推出以来，该公司的平台增长迅速且利润丰厚，已被全球15大生物制药公司和美国近一半的综合癌症中心采用。</blockquote> BiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.<blockquote>生物技术忒修斯制药公司(THRX)计划以5.93亿美元的市值筹集1.25亿美元。Theseus的主要候选药物是胃肠道间质瘤(GIST)KIT激酶所有主要激活/耐药突变类别的泛变体抑制剂。该公司最近提交了高级GIST的IND，并计划在2021年第四季度晚期和2022年第一季度中部之间启动1/2期试验。</blockquote> Drug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.<blockquote>药物开发人员扣带(CING)计划以2.25亿美元的市值筹集5000万美元。其两种候选药物CTx-1301和CTx-1302正在开发用于治疗ADHD。该公司于2020年10月宣布了CTX-1301 1/2期研究的积极结果，并计划在2021年第四季度启动3期试验，预计将于2022年底获得结果。</blockquote> <img src=\"https://static.tigerbbs.com/610fa042e4de459e4597ed8086743234\" tg-width=\"1894\" tg-height=\"912\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.renaissancecapital.com/IPO-Center/News/86747/US-IPO-Week-Ahead-New-issuers-work-up-a-sweat-in-a-fitness-led-5-IPO-week\">Renaissance Capital</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ISO":"IsoPlexis Corp.","LTH":"Life Time Group Holdings, Inc.","THRX":"Theseus Pharmaceuticals, Inc.","CING":"CINGULATE INC."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/86747/US-IPO-Week-Ahead-New-issuers-work-up-a-sweat-in-a-fitness-led-5-IPO-week","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186540865","content_text":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.\nFitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.\nFitness equipment brandiFIT Health & Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.\nProteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.\nBiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.\nDrug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.","news_type":1,"symbols_score_info":{"ISO":0.9,"IFIT":0.9,"CING":0.9,"THRX":0.9,"LTH":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":820039295,"gmtCreate":1633322345616,"gmtModify":1633322346069,"author":{"id":"3586451610703869","authorId":"3586451610703869","name":"KH321","avatar":"https://static.tigerbbs.com/c1bb8bd7d6d5df5f9732871fe60999ea","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586451610703869","authorIdStr":"3586451610703869"},"htmlText":"OK","listText":"OK","text":"OK","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/820039295","repostId":1186540865,"repostType":4,"repost":{"id":"1186540865","kind":"news","pubTimestamp":1633289898,"share":"https://www.laohu8.com/m/news/1186540865?lang=zh_CN&edition=full","pubTime":"2021-10-04 03:38","market":"us","language":"en","title":"US IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1186540865","media":"Renaissance Capital","summary":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness co","content":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.<blockquote>在10月的第一周，由两家健身公司牵头的五起IPO预计将筹集18亿美元。</blockquote> Fitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.<blockquote>健身连锁生命时代集团控股(LTH)计划以41亿美元的市值筹集9.01亿美元。Life Time于2015年私有化，在美国29个州和加拿大一个省运营着150多个“中心”，截至2011年7月31日，为近140万个人会员提供服务。尽管该公司受到疫情的严重打击，但此后运营情况显着改善，2021年第二季度的收入翻了两番。</blockquote> Fitness equipment brandiFIT Health &amp; Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.<blockquote>健身器材品牌iFIT健康与健身(IFIT)计划以64亿美元的市值筹集6亿美元。iFIT是美国排名第一的大型健身器材供应商，销售品牌包括iFIT、NordicTrack、ProForm和Freemotion。该公司发展迅速，但尚未盈利，为120多个国家的超过610万会员和150万订户提供服务。</blockquote> Proteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.<blockquote>蛋白质组学平台等丛(ISO)计划以6.48亿美元的市值筹集1.25亿美元。IsoPlexis认为其平台是第一个同时采用蛋白质组学和单细胞生物学来表征细胞功能并将其与患者结果联系起来的平台。自2018年6月商业推出以来，该公司的平台增长迅速且利润丰厚，已被全球15大生物制药公司和美国近一半的综合癌症中心采用。</blockquote> BiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.<blockquote>生物技术忒修斯制药公司(THRX)计划以5.93亿美元的市值筹集1.25亿美元。Theseus的主要候选药物是胃肠道间质瘤(GIST)KIT激酶所有主要激活/耐药突变类别的泛变体抑制剂。该公司最近提交了高级GIST的IND，并计划在2021年第四季度晚期和2022年第一季度中部之间启动1/2期试验。</blockquote> Drug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.<blockquote>药物开发人员扣带(CING)计划以2.25亿美元的市值筹集5000万美元。其两种候选药物CTx-1301和CTx-1302正在开发用于治疗ADHD。该公司于2020年10月宣布了CTX-1301 1/2期研究的积极结果，并计划在2021年第四季度启动3期试验，预计将于2022年底获得结果。</blockquote> <img src=\"https://static.tigerbbs.com/610fa042e4de459e4597ed8086743234\" tg-width=\"1894\" tg-height=\"912\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nRenaissance Capital2021-10-04 03:38\n\n</h4>\n</header>\n<article>\nIn the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.<blockquote>在10月的第一周，由两家健身公司牵头的五起IPO预计将筹集18亿美元。</blockquote> Fitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.<blockquote>健身连锁生命时代集团控股(LTH)计划以41亿美元的市值筹集9.01亿美元。Life Time于2015年私有化，在美国29个州和加拿大一个省运营着150多个“中心”，截至2011年7月31日，为近140万个人会员提供服务。尽管该公司受到疫情的严重打击，但此后运营情况显着改善，2021年第二季度的收入翻了两番。</blockquote> Fitness equipment brandiFIT Health &amp; Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.<blockquote>健身器材品牌iFIT健康与健身(IFIT)计划以64亿美元的市值筹集6亿美元。iFIT是美国排名第一的大型健身器材供应商，销售品牌包括iFIT、NordicTrack、ProForm和Freemotion。该公司发展迅速，但尚未盈利，为120多个国家的超过610万会员和150万订户提供服务。</blockquote> Proteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.<blockquote>蛋白质组学平台等丛(ISO)计划以6.48亿美元的市值筹集1.25亿美元。IsoPlexis认为其平台是第一个同时采用蛋白质组学和单细胞生物学来表征细胞功能并将其与患者结果联系起来的平台。自2018年6月商业推出以来，该公司的平台增长迅速且利润丰厚，已被全球15大生物制药公司和美国近一半的综合癌症中心采用。</blockquote> BiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.<blockquote>生物技术忒修斯制药公司(THRX)计划以5.93亿美元的市值筹集1.25亿美元。Theseus的主要候选药物是胃肠道间质瘤(GIST)KIT激酶所有主要激活/耐药突变类别的泛变体抑制剂。该公司最近提交了高级GIST的IND，并计划在2021年第四季度晚期和2022年第一季度中部之间启动1/2期试验。</blockquote> Drug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.<blockquote>药物开发人员扣带(CING)计划以2.25亿美元的市值筹集5000万美元。其两种候选药物CTx-1301和CTx-1302正在开发用于治疗ADHD。该公司于2020年10月宣布了CTX-1301 1/2期研究的积极结果，并计划在2021年第四季度启动3期试验，预计将于2022年底获得结果。</blockquote> <img src=\"https://static.tigerbbs.com/610fa042e4de459e4597ed8086743234\" tg-width=\"1894\" tg-height=\"912\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.renaissancecapital.com/IPO-Center/News/86747/US-IPO-Week-Ahead-New-issuers-work-up-a-sweat-in-a-fitness-led-5-IPO-week\">Renaissance Capital</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ISO":"IsoPlexis Corp.","LTH":"Life Time Group Holdings, Inc.","THRX":"Theseus Pharmaceuticals, Inc.","CING":"CINGULATE INC."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/86747/US-IPO-Week-Ahead-New-issuers-work-up-a-sweat-in-a-fitness-led-5-IPO-week","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186540865","content_text":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.\nFitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.\nFitness equipment brandiFIT Health & Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.\nProteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.\nBiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.\nDrug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.","news_type":1,"symbols_score_info":{"ISO":0.9,"IFIT":0.9,"CING":0.9,"THRX":0.9,"LTH":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":820094772,"gmtCreate":1633321951661,"gmtModify":1633321952761,"author":{"id":"3581317711527033","authorId":"3581317711527033","name":"Chanelyap","avatar":"https://static.tigerbbs.com/ead5a4e57e2f9f018e7802a33c0a28f5","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3581317711527033","authorIdStr":"3581317711527033"},"htmlText":"Like thanks","listText":"Like thanks","text":"Like thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/820094772","repostId":1186540865,"repostType":4,"repost":{"id":"1186540865","kind":"news","pubTimestamp":1633289898,"share":"https://www.laohu8.com/m/news/1186540865?lang=zh_CN&edition=full","pubTime":"2021-10-04 03:38","market":"us","language":"en","title":"US IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1186540865","media":"Renaissance Capital","summary":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness co","content":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.<blockquote>在10月的第一周，由两家健身公司牵头的五起IPO预计将筹集18亿美元。</blockquote> Fitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.<blockquote>健身连锁生命时代集团控股(LTH)计划以41亿美元的市值筹集9.01亿美元。Life Time于2015年私有化，在美国29个州和加拿大一个省运营着150多个“中心”，截至2011年7月31日，为近140万个人会员提供服务。尽管该公司受到疫情的严重打击，但此后运营情况显着改善，2021年第二季度的收入翻了两番。</blockquote> Fitness equipment brandiFIT Health &amp; Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.<blockquote>健身器材品牌iFIT健康与健身(IFIT)计划以64亿美元的市值筹集6亿美元。iFIT是美国排名第一的大型健身器材供应商，销售品牌包括iFIT、NordicTrack、ProForm和Freemotion。该公司发展迅速，但尚未盈利，为120多个国家的超过610万会员和150万订户提供服务。</blockquote> Proteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.<blockquote>蛋白质组学平台等丛(ISO)计划以6.48亿美元的市值筹集1.25亿美元。IsoPlexis认为其平台是第一个同时采用蛋白质组学和单细胞生物学来表征细胞功能并将其与患者结果联系起来的平台。自2018年6月商业推出以来，该公司的平台增长迅速且利润丰厚，已被全球15大生物制药公司和美国近一半的综合癌症中心采用。</blockquote> BiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.<blockquote>生物技术忒修斯制药公司(THRX)计划以5.93亿美元的市值筹集1.25亿美元。Theseus的主要候选药物是胃肠道间质瘤(GIST)KIT激酶所有主要激活/耐药突变类别的泛变体抑制剂。该公司最近提交了高级GIST的IND，并计划在2021年第四季度晚期和2022年第一季度中部之间启动1/2期试验。</blockquote> Drug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.<blockquote>药物开发人员扣带(CING)计划以2.25亿美元的市值筹集5000万美元。其两种候选药物CTx-1301和CTx-1302正在开发用于治疗ADHD。该公司于2020年10月宣布了CTX-1301 1/2期研究的积极结果，并计划在2021年第四季度启动3期试验，预计将于2022年底获得结果。</blockquote> <img src=\"https://static.tigerbbs.com/610fa042e4de459e4597ed8086743234\" tg-width=\"1894\" tg-height=\"912\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nRenaissance Capital2021-10-04 03:38\n\n</h4>\n</header>\n<article>\nIn the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.<blockquote>在10月的第一周，由两家健身公司牵头的五起IPO预计将筹集18亿美元。</blockquote> Fitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.<blockquote>健身连锁生命时代集团控股(LTH)计划以41亿美元的市值筹集9.01亿美元。Life Time于2015年私有化，在美国29个州和加拿大一个省运营着150多个“中心”，截至2011年7月31日，为近140万个人会员提供服务。尽管该公司受到疫情的严重打击，但此后运营情况显着改善，2021年第二季度的收入翻了两番。</blockquote> Fitness equipment brandiFIT Health &amp; Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.<blockquote>健身器材品牌iFIT健康与健身(IFIT)计划以64亿美元的市值筹集6亿美元。iFIT是美国排名第一的大型健身器材供应商，销售品牌包括iFIT、NordicTrack、ProForm和Freemotion。该公司发展迅速，但尚未盈利，为120多个国家的超过610万会员和150万订户提供服务。</blockquote> Proteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.<blockquote>蛋白质组学平台等丛(ISO)计划以6.48亿美元的市值筹集1.25亿美元。IsoPlexis认为其平台是第一个同时采用蛋白质组学和单细胞生物学来表征细胞功能并将其与患者结果联系起来的平台。自2018年6月商业推出以来，该公司的平台增长迅速且利润丰厚，已被全球15大生物制药公司和美国近一半的综合癌症中心采用。</blockquote> BiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.<blockquote>生物技术忒修斯制药公司(THRX)计划以5.93亿美元的市值筹集1.25亿美元。Theseus的主要候选药物是胃肠道间质瘤(GIST)KIT激酶所有主要激活/耐药突变类别的泛变体抑制剂。该公司最近提交了高级GIST的IND，并计划在2021年第四季度晚期和2022年第一季度中部之间启动1/2期试验。</blockquote> Drug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.<blockquote>药物开发人员扣带(CING)计划以2.25亿美元的市值筹集5000万美元。其两种候选药物CTx-1301和CTx-1302正在开发用于治疗ADHD。该公司于2020年10月宣布了CTX-1301 1/2期研究的积极结果，并计划在2021年第四季度启动3期试验，预计将于2022年底获得结果。</blockquote> <img src=\"https://static.tigerbbs.com/610fa042e4de459e4597ed8086743234\" tg-width=\"1894\" tg-height=\"912\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.renaissancecapital.com/IPO-Center/News/86747/US-IPO-Week-Ahead-New-issuers-work-up-a-sweat-in-a-fitness-led-5-IPO-week\">Renaissance Capital</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ISO":"IsoPlexis Corp.","LTH":"Life Time Group Holdings, Inc.","THRX":"Theseus Pharmaceuticals, Inc.","CING":"CINGULATE INC."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/86747/US-IPO-Week-Ahead-New-issuers-work-up-a-sweat-in-a-fitness-led-5-IPO-week","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186540865","content_text":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.\nFitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.\nFitness equipment brandiFIT Health & Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.\nProteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.\nBiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.\nDrug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.","news_type":1,"symbols_score_info":{"ISO":0.9,"IFIT":0.9,"CING":0.9,"THRX":0.9,"LTH":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6086151,"gmtCreate":1633322030666,"gmtModify":1634722491955,"authorId":3581346389720502,"author":{"id":3581346389720502,"idStr":"3581346389720502","authorId":3581346389720502,"name":"hello369","avatar":"https://static.tigerbbs.com/6f472aef15b4385af1feba4d7bd16e06","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":820094772,"type":1,"supId":0,"prevId":0,"content":"Done","text":"Done","html":"Done"},{"id":6093097,"gmtCreate":1633389821864,"gmtModify":1634721931111,"authorId":3567307840510045,"author":{"id":3567307840510045,"idStr":"3567307840510045","authorId":3567307840510045,"name":"JeremyKok","avatar":"https://static.tigerbbs.com/01b03a485f83b6b2615fad8ac9b87bf4","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":820094772,"type":1,"supId":0,"prevId":0,"content":"hi. please like and comment back. thank you.","text":"hi. please like and comment back. thank you.","html":"hi. please like and comment back. thank you."}],"langContent":"CN"},{"id":820094481,"gmtCreate":1633321951066,"gmtModify":1633321951412,"author":{"id":"3580689210488653","authorId":"3580689210488653","name":"SilentWarrio","avatar":"https://static.tigerbbs.com/c904a9b7d64fe6eb5230d2a57a74ffee","vip":1,"crmLevel":12,"crmLevelSwitch":0,"idStr":"3580689210488653","authorIdStr":"3580689210488653"},"htmlText":"Is this a good time to buy? So much uncertainties...","listText":"Is this a good time to buy? So much uncertainties...","text":"Is this a good time to buy? So much uncertainties...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/820094481","repostId":1186540865,"repostType":4,"repost":{"id":"1186540865","kind":"news","pubTimestamp":1633289898,"share":"https://www.laohu8.com/m/news/1186540865?lang=zh_CN&edition=full","pubTime":"2021-10-04 03:38","market":"us","language":"en","title":"US IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1186540865","media":"Renaissance Capital","summary":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness co","content":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.<blockquote>在10月的第一周，由两家健身公司牵头的五起IPO预计将筹集18亿美元。</blockquote> Fitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.<blockquote>健身连锁生命时代集团控股(LTH)计划以41亿美元的市值筹集9.01亿美元。Life Time于2015年私有化，在美国29个州和加拿大一个省运营着150多个“中心”，截至2011年7月31日，为近140万个人会员提供服务。尽管该公司受到疫情的严重打击，但此后运营情况显着改善，2021年第二季度的收入翻了两番。</blockquote> Fitness equipment brandiFIT Health &amp; Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.<blockquote>健身器材品牌iFIT健康与健身(IFIT)计划以64亿美元的市值筹集6亿美元。iFIT是美国排名第一的大型健身器材供应商，销售品牌包括iFIT、NordicTrack、ProForm和Freemotion。该公司发展迅速，但尚未盈利，为120多个国家的超过610万会员和150万订户提供服务。</blockquote> Proteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.<blockquote>蛋白质组学平台等丛(ISO)计划以6.48亿美元的市值筹集1.25亿美元。IsoPlexis认为其平台是第一个同时采用蛋白质组学和单细胞生物学来表征细胞功能并将其与患者结果联系起来的平台。自2018年6月商业推出以来，该公司的平台增长迅速且利润丰厚，已被全球15大生物制药公司和美国近一半的综合癌症中心采用。</blockquote> BiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.<blockquote>生物技术忒修斯制药公司(THRX)计划以5.93亿美元的市值筹集1.25亿美元。Theseus的主要候选药物是胃肠道间质瘤(GIST)KIT激酶所有主要激活/耐药突变类别的泛变体抑制剂。该公司最近提交了高级GIST的IND，并计划在2021年第四季度晚期和2022年第一季度中部之间启动1/2期试验。</blockquote> Drug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.<blockquote>药物开发人员扣带(CING)计划以2.25亿美元的市值筹集5000万美元。其两种候选药物CTx-1301和CTx-1302正在开发用于治疗ADHD。该公司于2020年10月宣布了CTX-1301 1/2期研究的积极结果，并计划在2021年第四季度启动3期试验，预计将于2022年底获得结果。</blockquote> <img src=\"https://static.tigerbbs.com/610fa042e4de459e4597ed8086743234\" tg-width=\"1894\" tg-height=\"912\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nRenaissance Capital2021-10-04 03:38\n\n</h4>\n</header>\n<article>\nIn the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.<blockquote>在10月的第一周，由两家健身公司牵头的五起IPO预计将筹集18亿美元。</blockquote> Fitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.<blockquote>健身连锁生命时代集团控股(LTH)计划以41亿美元的市值筹集9.01亿美元。Life Time于2015年私有化，在美国29个州和加拿大一个省运营着150多个“中心”，截至2011年7月31日，为近140万个人会员提供服务。尽管该公司受到疫情的严重打击，但此后运营情况显着改善，2021年第二季度的收入翻了两番。</blockquote> Fitness equipment brandiFIT Health &amp; Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.<blockquote>健身器材品牌iFIT健康与健身(IFIT)计划以64亿美元的市值筹集6亿美元。iFIT是美国排名第一的大型健身器材供应商，销售品牌包括iFIT、NordicTrack、ProForm和Freemotion。该公司发展迅速，但尚未盈利，为120多个国家的超过610万会员和150万订户提供服务。</blockquote> Proteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.<blockquote>蛋白质组学平台等丛(ISO)计划以6.48亿美元的市值筹集1.25亿美元。IsoPlexis认为其平台是第一个同时采用蛋白质组学和单细胞生物学来表征细胞功能并将其与患者结果联系起来的平台。自2018年6月商业推出以来，该公司的平台增长迅速且利润丰厚，已被全球15大生物制药公司和美国近一半的综合癌症中心采用。</blockquote> BiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.<blockquote>生物技术忒修斯制药公司(THRX)计划以5.93亿美元的市值筹集1.25亿美元。Theseus的主要候选药物是胃肠道间质瘤(GIST)KIT激酶所有主要激活/耐药突变类别的泛变体抑制剂。该公司最近提交了高级GIST的IND，并计划在2021年第四季度晚期和2022年第一季度中部之间启动1/2期试验。</blockquote> Drug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.<blockquote>药物开发人员扣带(CING)计划以2.25亿美元的市值筹集5000万美元。其两种候选药物CTx-1301和CTx-1302正在开发用于治疗ADHD。该公司于2020年10月宣布了CTX-1301 1/2期研究的积极结果，并计划在2021年第四季度启动3期试验，预计将于2022年底获得结果。</blockquote> <img src=\"https://static.tigerbbs.com/610fa042e4de459e4597ed8086743234\" tg-width=\"1894\" tg-height=\"912\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.renaissancecapital.com/IPO-Center/News/86747/US-IPO-Week-Ahead-New-issuers-work-up-a-sweat-in-a-fitness-led-5-IPO-week\">Renaissance Capital</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ISO":"IsoPlexis Corp.","LTH":"Life Time Group Holdings, Inc.","THRX":"Theseus Pharmaceuticals, Inc.","CING":"CINGULATE INC."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/86747/US-IPO-Week-Ahead-New-issuers-work-up-a-sweat-in-a-fitness-led-5-IPO-week","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186540865","content_text":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.\nFitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.\nFitness equipment brandiFIT Health & Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.\nProteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.\nBiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.\nDrug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.","news_type":1,"symbols_score_info":{"ISO":0.9,"IFIT":0.9,"CING":0.9,"THRX":0.9,"LTH":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6086522,"gmtCreate":1633325124297,"gmtModify":1634722457414,"authorId":3571044771112848,"author":{"id":3571044771112848,"idStr":"3571044771112848","authorId":3571044771112848,"name":"ming22","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":820094481,"type":1,"supId":0,"prevId":0,"content":"Ya, have some concern too","text":"Ya, have some concern too","html":"Ya, have some concern too"}],"langContent":"CN"},{"id":820092994,"gmtCreate":1633321717265,"gmtModify":1633321717830,"author":{"id":"3581331692871918","authorId":"3581331692871918","name":"beebeeyan","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3581331692871918","authorIdStr":"3581331692871918"},"htmlText":"oh","listText":"oh","text":"oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/820092994","repostId":1186540865,"repostType":4,"repost":{"id":"1186540865","kind":"news","pubTimestamp":1633289898,"share":"https://www.laohu8.com/m/news/1186540865?lang=zh_CN&edition=full","pubTime":"2021-10-04 03:38","market":"us","language":"en","title":"US IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1186540865","media":"Renaissance Capital","summary":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness co","content":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.<blockquote>在10月的第一周，由两家健身公司牵头的五起IPO预计将筹集18亿美元。</blockquote> Fitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.<blockquote>健身连锁生命时代集团控股(LTH)计划以41亿美元的市值筹集9.01亿美元。Life Time于2015年私有化，在美国29个州和加拿大一个省运营着150多个“中心”，截至2011年7月31日，为近140万个人会员提供服务。尽管该公司受到疫情的严重打击，但此后运营情况显着改善，2021年第二季度的收入翻了两番。</blockquote> Fitness equipment brandiFIT Health &amp; Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.<blockquote>健身器材品牌iFIT健康与健身(IFIT)计划以64亿美元的市值筹集6亿美元。iFIT是美国排名第一的大型健身器材供应商，销售品牌包括iFIT、NordicTrack、ProForm和Freemotion。该公司发展迅速，但尚未盈利，为120多个国家的超过610万会员和150万订户提供服务。</blockquote> Proteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.<blockquote>蛋白质组学平台等丛(ISO)计划以6.48亿美元的市值筹集1.25亿美元。IsoPlexis认为其平台是第一个同时采用蛋白质组学和单细胞生物学来表征细胞功能并将其与患者结果联系起来的平台。自2018年6月商业推出以来，该公司的平台增长迅速且利润丰厚，已被全球15大生物制药公司和美国近一半的综合癌症中心采用。</blockquote> BiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.<blockquote>生物技术忒修斯制药公司(THRX)计划以5.93亿美元的市值筹集1.25亿美元。Theseus的主要候选药物是胃肠道间质瘤(GIST)KIT激酶所有主要激活/耐药突变类别的泛变体抑制剂。该公司最近提交了高级GIST的IND，并计划在2021年第四季度晚期和2022年第一季度中部之间启动1/2期试验。</blockquote> Drug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.<blockquote>药物开发人员扣带(CING)计划以2.25亿美元的市值筹集5000万美元。其两种候选药物CTx-1301和CTx-1302正在开发用于治疗ADHD。该公司于2020年10月宣布了CTX-1301 1/2期研究的积极结果，并计划在2021年第四季度启动3期试验，预计将于2022年底获得结果。</blockquote> <img src=\"https://static.tigerbbs.com/610fa042e4de459e4597ed8086743234\" tg-width=\"1894\" tg-height=\"912\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nRenaissance Capital2021-10-04 03:38\n\n</h4>\n</header>\n<article>\nIn the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.<blockquote>在10月的第一周，由两家健身公司牵头的五起IPO预计将筹集18亿美元。</blockquote> Fitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.<blockquote>健身连锁生命时代集团控股(LTH)计划以41亿美元的市值筹集9.01亿美元。Life Time于2015年私有化，在美国29个州和加拿大一个省运营着150多个“中心”，截至2011年7月31日，为近140万个人会员提供服务。尽管该公司受到疫情的严重打击，但此后运营情况显着改善，2021年第二季度的收入翻了两番。</blockquote> Fitness equipment brandiFIT Health &amp; Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.<blockquote>健身器材品牌iFIT健康与健身(IFIT)计划以64亿美元的市值筹集6亿美元。iFIT是美国排名第一的大型健身器材供应商，销售品牌包括iFIT、NordicTrack、ProForm和Freemotion。该公司发展迅速，但尚未盈利，为120多个国家的超过610万会员和150万订户提供服务。</blockquote> Proteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.<blockquote>蛋白质组学平台等丛(ISO)计划以6.48亿美元的市值筹集1.25亿美元。IsoPlexis认为其平台是第一个同时采用蛋白质组学和单细胞生物学来表征细胞功能并将其与患者结果联系起来的平台。自2018年6月商业推出以来，该公司的平台增长迅速且利润丰厚，已被全球15大生物制药公司和美国近一半的综合癌症中心采用。</blockquote> BiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.<blockquote>生物技术忒修斯制药公司(THRX)计划以5.93亿美元的市值筹集1.25亿美元。Theseus的主要候选药物是胃肠道间质瘤(GIST)KIT激酶所有主要激活/耐药突变类别的泛变体抑制剂。该公司最近提交了高级GIST的IND，并计划在2021年第四季度晚期和2022年第一季度中部之间启动1/2期试验。</blockquote> Drug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.<blockquote>药物开发人员扣带(CING)计划以2.25亿美元的市值筹集5000万美元。其两种候选药物CTx-1301和CTx-1302正在开发用于治疗ADHD。该公司于2020年10月宣布了CTX-1301 1/2期研究的积极结果，并计划在2021年第四季度启动3期试验，预计将于2022年底获得结果。</blockquote> <img src=\"https://static.tigerbbs.com/610fa042e4de459e4597ed8086743234\" tg-width=\"1894\" tg-height=\"912\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.renaissancecapital.com/IPO-Center/News/86747/US-IPO-Week-Ahead-New-issuers-work-up-a-sweat-in-a-fitness-led-5-IPO-week\">Renaissance Capital</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ISO":"IsoPlexis Corp.","LTH":"Life Time Group Holdings, Inc.","THRX":"Theseus Pharmaceuticals, Inc.","CING":"CINGULATE INC."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/86747/US-IPO-Week-Ahead-New-issuers-work-up-a-sweat-in-a-fitness-led-5-IPO-week","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186540865","content_text":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.\nFitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.\nFitness equipment brandiFIT Health & Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.\nProteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.\nBiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.\nDrug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.","news_type":1,"symbols_score_info":{"ISO":0.9,"IFIT":0.9,"CING":0.9,"THRX":0.9,"LTH":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":820092035,"gmtCreate":1633321692141,"gmtModify":1633321692460,"author":{"id":"4087109479010510","authorId":"4087109479010510","name":"Tamashii","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"4087109479010510","authorIdStr":"4087109479010510"},"htmlText":"Good luck","listText":"Good luck","text":"Good luck","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/820092035","repostId":1186540865,"repostType":4,"repost":{"id":"1186540865","kind":"news","pubTimestamp":1633289898,"share":"https://www.laohu8.com/m/news/1186540865?lang=zh_CN&edition=full","pubTime":"2021-10-04 03:38","market":"us","language":"en","title":"US IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1186540865","media":"Renaissance Capital","summary":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness co","content":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.<blockquote>在10月的第一周，由两家健身公司牵头的五起IPO预计将筹集18亿美元。</blockquote> Fitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.<blockquote>健身连锁生命时代集团控股(LTH)计划以41亿美元的市值筹集9.01亿美元。Life Time于2015年私有化，在美国29个州和加拿大一个省运营着150多个“中心”，截至2011年7月31日，为近140万个人会员提供服务。尽管该公司受到疫情的严重打击，但此后运营情况显着改善，2021年第二季度的收入翻了两番。</blockquote> Fitness equipment brandiFIT Health &amp; Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.<blockquote>健身器材品牌iFIT健康与健身(IFIT)计划以64亿美元的市值筹集6亿美元。iFIT是美国排名第一的大型健身器材供应商，销售品牌包括iFIT、NordicTrack、ProForm和Freemotion。该公司发展迅速，但尚未盈利，为120多个国家的超过610万会员和150万订户提供服务。</blockquote> Proteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.<blockquote>蛋白质组学平台等丛(ISO)计划以6.48亿美元的市值筹集1.25亿美元。IsoPlexis认为其平台是第一个同时采用蛋白质组学和单细胞生物学来表征细胞功能并将其与患者结果联系起来的平台。自2018年6月商业推出以来，该公司的平台增长迅速且利润丰厚，已被全球15大生物制药公司和美国近一半的综合癌症中心采用。</blockquote> BiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.<blockquote>生物技术忒修斯制药公司(THRX)计划以5.93亿美元的市值筹集1.25亿美元。Theseus的主要候选药物是胃肠道间质瘤(GIST)KIT激酶所有主要激活/耐药突变类别的泛变体抑制剂。该公司最近提交了高级GIST的IND，并计划在2021年第四季度晚期和2022年第一季度中部之间启动1/2期试验。</blockquote> Drug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.<blockquote>药物开发人员扣带(CING)计划以2.25亿美元的市值筹集5000万美元。其两种候选药物CTx-1301和CTx-1302正在开发用于治疗ADHD。该公司于2020年10月宣布了CTX-1301 1/2期研究的积极结果，并计划在2021年第四季度启动3期试验，预计将于2022年底获得结果。</blockquote> <img src=\"https://static.tigerbbs.com/610fa042e4de459e4597ed8086743234\" tg-width=\"1894\" tg-height=\"912\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nRenaissance Capital2021-10-04 03:38\n\n</h4>\n</header>\n<article>\nIn the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.<blockquote>在10月的第一周，由两家健身公司牵头的五起IPO预计将筹集18亿美元。</blockquote> Fitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.<blockquote>健身连锁生命时代集团控股(LTH)计划以41亿美元的市值筹集9.01亿美元。Life Time于2015年私有化，在美国29个州和加拿大一个省运营着150多个“中心”，截至2011年7月31日，为近140万个人会员提供服务。尽管该公司受到疫情的严重打击，但此后运营情况显着改善，2021年第二季度的收入翻了两番。</blockquote> Fitness equipment brandiFIT Health &amp; Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.<blockquote>健身器材品牌iFIT健康与健身(IFIT)计划以64亿美元的市值筹集6亿美元。iFIT是美国排名第一的大型健身器材供应商，销售品牌包括iFIT、NordicTrack、ProForm和Freemotion。该公司发展迅速，但尚未盈利，为120多个国家的超过610万会员和150万订户提供服务。</blockquote> Proteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.<blockquote>蛋白质组学平台等丛(ISO)计划以6.48亿美元的市值筹集1.25亿美元。IsoPlexis认为其平台是第一个同时采用蛋白质组学和单细胞生物学来表征细胞功能并将其与患者结果联系起来的平台。自2018年6月商业推出以来，该公司的平台增长迅速且利润丰厚，已被全球15大生物制药公司和美国近一半的综合癌症中心采用。</blockquote> BiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.<blockquote>生物技术忒修斯制药公司(THRX)计划以5.93亿美元的市值筹集1.25亿美元。Theseus的主要候选药物是胃肠道间质瘤(GIST)KIT激酶所有主要激活/耐药突变类别的泛变体抑制剂。该公司最近提交了高级GIST的IND，并计划在2021年第四季度晚期和2022年第一季度中部之间启动1/2期试验。</blockquote> Drug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.<blockquote>药物开发人员扣带(CING)计划以2.25亿美元的市值筹集5000万美元。其两种候选药物CTx-1301和CTx-1302正在开发用于治疗ADHD。该公司于2020年10月宣布了CTX-1301 1/2期研究的积极结果，并计划在2021年第四季度启动3期试验，预计将于2022年底获得结果。</blockquote> <img src=\"https://static.tigerbbs.com/610fa042e4de459e4597ed8086743234\" tg-width=\"1894\" tg-height=\"912\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.renaissancecapital.com/IPO-Center/News/86747/US-IPO-Week-Ahead-New-issuers-work-up-a-sweat-in-a-fitness-led-5-IPO-week\">Renaissance Capital</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ISO":"IsoPlexis Corp.","LTH":"Life Time Group Holdings, Inc.","THRX":"Theseus Pharmaceuticals, Inc.","CING":"CINGULATE INC."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/86747/US-IPO-Week-Ahead-New-issuers-work-up-a-sweat-in-a-fitness-led-5-IPO-week","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186540865","content_text":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.\nFitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.\nFitness equipment brandiFIT Health & Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.\nProteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.\nBiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.\nDrug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.","news_type":1,"symbols_score_info":{"ISO":0.9,"IFIT":0.9,"CING":0.9,"THRX":0.9,"LTH":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6086122,"gmtCreate":1633321722141,"gmtModify":1634722494783,"authorId":3581331692871918,"author":{"id":3581331692871918,"idStr":"3581331692871918","authorId":3581331692871918,"name":"beebeeyan","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":820092035,"type":1,"supId":0,"prevId":0,"content":"oh","text":"oh","html":"oh"}],"langContent":"CN"},{"id":820000540,"gmtCreate":1633320096941,"gmtModify":1633320097273,"author":{"id":"3578658486074975","authorId":"3578658486074975","name":"PEPESZ","avatar":"https://static.tigerbbs.com/ebaf682b46c1f56e5c38680b33a78d5f","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3578658486074975","authorIdStr":"3578658486074975"},"htmlText":"Like pls, thx!","listText":"Like pls, thx!","text":"Like pls, thx!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/820000540","repostId":1186540865,"repostType":4,"repost":{"id":"1186540865","kind":"news","pubTimestamp":1633289898,"share":"https://www.laohu8.com/m/news/1186540865?lang=zh_CN&edition=full","pubTime":"2021-10-04 03:38","market":"us","language":"en","title":"US IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1186540865","media":"Renaissance Capital","summary":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness co","content":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.<blockquote>在10月的第一周，由两家健身公司牵头的五起IPO预计将筹集18亿美元。</blockquote> Fitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.<blockquote>健身连锁生命时代集团控股(LTH)计划以41亿美元的市值筹集9.01亿美元。Life Time于2015年私有化，在美国29个州和加拿大一个省运营着150多个“中心”，截至2011年7月31日，为近140万个人会员提供服务。尽管该公司受到疫情的严重打击，但此后运营情况显着改善，2021年第二季度的收入翻了两番。</blockquote> Fitness equipment brandiFIT Health &amp; Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.<blockquote>健身器材品牌iFIT健康与健身(IFIT)计划以64亿美元的市值筹集6亿美元。iFIT是美国排名第一的大型健身器材供应商，销售品牌包括iFIT、NordicTrack、ProForm和Freemotion。该公司发展迅速，但尚未盈利，为120多个国家的超过610万会员和150万订户提供服务。</blockquote> Proteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.<blockquote>蛋白质组学平台等丛(ISO)计划以6.48亿美元的市值筹集1.25亿美元。IsoPlexis认为其平台是第一个同时采用蛋白质组学和单细胞生物学来表征细胞功能并将其与患者结果联系起来的平台。自2018年6月商业推出以来，该公司的平台增长迅速且利润丰厚，已被全球15大生物制药公司和美国近一半的综合癌症中心采用。</blockquote> BiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.<blockquote>生物技术忒修斯制药公司(THRX)计划以5.93亿美元的市值筹集1.25亿美元。Theseus的主要候选药物是胃肠道间质瘤(GIST)KIT激酶所有主要激活/耐药突变类别的泛变体抑制剂。该公司最近提交了高级GIST的IND，并计划在2021年第四季度晚期和2022年第一季度中部之间启动1/2期试验。</blockquote> Drug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.<blockquote>药物开发人员扣带(CING)计划以2.25亿美元的市值筹集5000万美元。其两种候选药物CTx-1301和CTx-1302正在开发用于治疗ADHD。该公司于2020年10月宣布了CTX-1301 1/2期研究的积极结果，并计划在2021年第四季度启动3期试验，预计将于2022年底获得结果。</blockquote> <img src=\"https://static.tigerbbs.com/610fa042e4de459e4597ed8086743234\" tg-width=\"1894\" tg-height=\"912\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nRenaissance Capital2021-10-04 03:38\n\n</h4>\n</header>\n<article>\nIn the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.<blockquote>在10月的第一周，由两家健身公司牵头的五起IPO预计将筹集18亿美元。</blockquote> Fitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.<blockquote>健身连锁生命时代集团控股(LTH)计划以41亿美元的市值筹集9.01亿美元。Life Time于2015年私有化，在美国29个州和加拿大一个省运营着150多个“中心”，截至2011年7月31日，为近140万个人会员提供服务。尽管该公司受到疫情的严重打击，但此后运营情况显着改善，2021年第二季度的收入翻了两番。</blockquote> Fitness equipment brandiFIT Health &amp; Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.<blockquote>健身器材品牌iFIT健康与健身(IFIT)计划以64亿美元的市值筹集6亿美元。iFIT是美国排名第一的大型健身器材供应商，销售品牌包括iFIT、NordicTrack、ProForm和Freemotion。该公司发展迅速，但尚未盈利，为120多个国家的超过610万会员和150万订户提供服务。</blockquote> Proteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.<blockquote>蛋白质组学平台等丛(ISO)计划以6.48亿美元的市值筹集1.25亿美元。IsoPlexis认为其平台是第一个同时采用蛋白质组学和单细胞生物学来表征细胞功能并将其与患者结果联系起来的平台。自2018年6月商业推出以来，该公司的平台增长迅速且利润丰厚，已被全球15大生物制药公司和美国近一半的综合癌症中心采用。</blockquote> BiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.<blockquote>生物技术忒修斯制药公司(THRX)计划以5.93亿美元的市值筹集1.25亿美元。Theseus的主要候选药物是胃肠道间质瘤(GIST)KIT激酶所有主要激活/耐药突变类别的泛变体抑制剂。该公司最近提交了高级GIST的IND，并计划在2021年第四季度晚期和2022年第一季度中部之间启动1/2期试验。</blockquote> Drug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.<blockquote>药物开发人员扣带(CING)计划以2.25亿美元的市值筹集5000万美元。其两种候选药物CTx-1301和CTx-1302正在开发用于治疗ADHD。该公司于2020年10月宣布了CTX-1301 1/2期研究的积极结果，并计划在2021年第四季度启动3期试验，预计将于2022年底获得结果。</blockquote> <img src=\"https://static.tigerbbs.com/610fa042e4de459e4597ed8086743234\" tg-width=\"1894\" tg-height=\"912\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.renaissancecapital.com/IPO-Center/News/86747/US-IPO-Week-Ahead-New-issuers-work-up-a-sweat-in-a-fitness-led-5-IPO-week\">Renaissance Capital</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ISO":"IsoPlexis Corp.","LTH":"Life Time Group Holdings, Inc.","THRX":"Theseus Pharmaceuticals, Inc.","CING":"CINGULATE INC."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/86747/US-IPO-Week-Ahead-New-issuers-work-up-a-sweat-in-a-fitness-led-5-IPO-week","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186540865","content_text":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.\nFitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.\nFitness equipment brandiFIT Health & Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.\nProteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.\nBiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.\nDrug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.","news_type":1,"symbols_score_info":{"ISO":0.9,"IFIT":0.9,"CING":0.9,"THRX":0.9,"LTH":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6093099,"gmtCreate":1633389831421,"gmtModify":1634721930893,"authorId":3567307840510045,"author":{"id":3567307840510045,"idStr":"3567307840510045","authorId":3567307840510045,"name":"JeremyKok","avatar":"https://static.tigerbbs.com/01b03a485f83b6b2615fad8ac9b87bf4","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":820000540,"type":1,"supId":0,"prevId":0,"content":"hi. please like and comment back. thank you.","text":"hi. please like and comment back. thank you.","html":"hi. please like and comment back. thank you."}],"langContent":"CN"},{"id":867770505,"gmtCreate":1633318828509,"gmtModify":1633318831775,"author":{"id":"3569316529855154","authorId":"3569316529855154","name":"Deonc","avatar":"https://static.tigerbbs.com/d9aa45dd2eb58357f6477dcfb99d1415","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3569316529855154","authorIdStr":"3569316529855154"},"htmlText":"New IPO.please like","listText":"New IPO.please like","text":"New IPO.please like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":11,"commentSize":7,"repostSize":0,"link":"https://laohu8.com/post/867770505","repostId":1186540865,"repostType":4,"repost":{"id":"1186540865","kind":"news","pubTimestamp":1633289898,"share":"https://www.laohu8.com/m/news/1186540865?lang=zh_CN&edition=full","pubTime":"2021-10-04 03:38","market":"us","language":"en","title":"US IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1186540865","media":"Renaissance Capital","summary":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness co","content":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.<blockquote>在10月的第一周，由两家健身公司牵头的五起IPO预计将筹集18亿美元。</blockquote> Fitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.<blockquote>健身连锁生命时代集团控股(LTH)计划以41亿美元的市值筹集9.01亿美元。Life Time于2015年私有化，在美国29个州和加拿大一个省运营着150多个“中心”，截至2011年7月31日，为近140万个人会员提供服务。尽管该公司受到疫情的严重打击，但此后运营情况显着改善，2021年第二季度的收入翻了两番。</blockquote> Fitness equipment brandiFIT Health &amp; Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.<blockquote>健身器材品牌iFIT健康与健身(IFIT)计划以64亿美元的市值筹集6亿美元。iFIT是美国排名第一的大型健身器材供应商，销售品牌包括iFIT、NordicTrack、ProForm和Freemotion。该公司发展迅速，但尚未盈利，为120多个国家的超过610万会员和150万订户提供服务。</blockquote> Proteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.<blockquote>蛋白质组学平台等丛(ISO)计划以6.48亿美元的市值筹集1.25亿美元。IsoPlexis认为其平台是第一个同时采用蛋白质组学和单细胞生物学来表征细胞功能并将其与患者结果联系起来的平台。自2018年6月商业推出以来，该公司的平台增长迅速且利润丰厚，已被全球15大生物制药公司和美国近一半的综合癌症中心采用。</blockquote> BiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.<blockquote>生物技术忒修斯制药公司(THRX)计划以5.93亿美元的市值筹集1.25亿美元。Theseus的主要候选药物是胃肠道间质瘤(GIST)KIT激酶所有主要激活/耐药突变类别的泛变体抑制剂。该公司最近提交了高级GIST的IND，并计划在2021年第四季度晚期和2022年第一季度中部之间启动1/2期试验。</blockquote> Drug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.<blockquote>药物开发人员扣带(CING)计划以2.25亿美元的市值筹集5000万美元。其两种候选药物CTx-1301和CTx-1302正在开发用于治疗ADHD。该公司于2020年10月宣布了CTX-1301 1/2期研究的积极结果，并计划在2021年第四季度启动3期试验，预计将于2022年底获得结果。</blockquote> <img src=\"https://static.tigerbbs.com/610fa042e4de459e4597ed8086743234\" tg-width=\"1894\" tg-height=\"912\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nRenaissance Capital2021-10-04 03:38\n\n</h4>\n</header>\n<article>\nIn the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.<blockquote>在10月的第一周，由两家健身公司牵头的五起IPO预计将筹集18亿美元。</blockquote> Fitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.<blockquote>健身连锁生命时代集团控股(LTH)计划以41亿美元的市值筹集9.01亿美元。Life Time于2015年私有化，在美国29个州和加拿大一个省运营着150多个“中心”，截至2011年7月31日，为近140万个人会员提供服务。尽管该公司受到疫情的严重打击，但此后运营情况显着改善，2021年第二季度的收入翻了两番。</blockquote> Fitness equipment brandiFIT Health &amp; Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.<blockquote>健身器材品牌iFIT健康与健身(IFIT)计划以64亿美元的市值筹集6亿美元。iFIT是美国排名第一的大型健身器材供应商，销售品牌包括iFIT、NordicTrack、ProForm和Freemotion。该公司发展迅速，但尚未盈利，为120多个国家的超过610万会员和150万订户提供服务。</blockquote> Proteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.<blockquote>蛋白质组学平台等丛(ISO)计划以6.48亿美元的市值筹集1.25亿美元。IsoPlexis认为其平台是第一个同时采用蛋白质组学和单细胞生物学来表征细胞功能并将其与患者结果联系起来的平台。自2018年6月商业推出以来，该公司的平台增长迅速且利润丰厚，已被全球15大生物制药公司和美国近一半的综合癌症中心采用。</blockquote> BiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.<blockquote>生物技术忒修斯制药公司(THRX)计划以5.93亿美元的市值筹集1.25亿美元。Theseus的主要候选药物是胃肠道间质瘤(GIST)KIT激酶所有主要激活/耐药突变类别的泛变体抑制剂。该公司最近提交了高级GIST的IND，并计划在2021年第四季度晚期和2022年第一季度中部之间启动1/2期试验。</blockquote> Drug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.<blockquote>药物开发人员扣带(CING)计划以2.25亿美元的市值筹集5000万美元。其两种候选药物CTx-1301和CTx-1302正在开发用于治疗ADHD。该公司于2020年10月宣布了CTX-1301 1/2期研究的积极结果，并计划在2021年第四季度启动3期试验，预计将于2022年底获得结果。</blockquote> <img src=\"https://static.tigerbbs.com/610fa042e4de459e4597ed8086743234\" tg-width=\"1894\" tg-height=\"912\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.renaissancecapital.com/IPO-Center/News/86747/US-IPO-Week-Ahead-New-issuers-work-up-a-sweat-in-a-fitness-led-5-IPO-week\">Renaissance Capital</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ISO":"IsoPlexis Corp.","LTH":"Life Time Group Holdings, Inc.","THRX":"Theseus Pharmaceuticals, Inc.","CING":"CINGULATE INC."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/86747/US-IPO-Week-Ahead-New-issuers-work-up-a-sweat-in-a-fitness-led-5-IPO-week","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186540865","content_text":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.\nFitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.\nFitness equipment brandiFIT Health & Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.\nProteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.\nBiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.\nDrug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.","news_type":1,"symbols_score_info":{"ISO":0.9,"IFIT":0.9,"CING":0.9,"THRX":0.9,"LTH":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6085726,"gmtCreate":1633318875192,"gmtModify":1634722527555,"authorId":3578544701064972,"author":{"id":3578544701064972,"idStr":"3578544701064972","authorId":3578544701064972,"name":"Joe0319","avatar":"https://static.tigerbbs.com/9b84d55e902f3cdc3167d94be984be1f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":867770505,"type":1,"supId":0,"prevId":0,"content":"ok","text":"ok","html":"ok"},{"id":6085895,"gmtCreate":1633320057623,"gmtModify":1634722514050,"authorId":3580379447244817,"author":{"id":3580379447244817,"idStr":"3580379447244817","authorId":3580379447244817,"name":"Haw75","avatar":"https://static.tigerbbs.com/b8a435feb2331b895463eca3c73cdb3f","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":867770505,"type":1,"supId":0,"prevId":0,"content":"latest","text":"latest","html":"latest"},{"id":6088026,"gmtCreate":1633341406519,"gmtModify":1634722338468,"authorId":3569316529855154,"author":{"id":3569316529855154,"idStr":"3569316529855154","authorId":3569316529855154,"name":"Deonc","avatar":"https://static.tigerbbs.com/d9aa45dd2eb58357f6477dcfb99d1415","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":867770505,"type":1,"supId":6085726,"prevId":0,"content":"thanks","text":"thanks","html":"thanks"},{"id":6088029,"gmtCreate":1633341416723,"gmtModify":1634722338142,"authorId":3569316529855154,"author":{"id":3569316529855154,"idStr":"3569316529855154","authorId":3569316529855154,"name":"Deonc","avatar":"https://static.tigerbbs.com/d9aa45dd2eb58357f6477dcfb99d1415","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":867770505,"type":1,"supId":6085895,"prevId":0,"content":"thanks","text":"thanks","html":"thanks"},{"id":6089216,"gmtCreate":1633351825416,"gmtModify":1634722244532,"authorId":3578544701064972,"author":{"id":3578544701064972,"idStr":"3578544701064972","authorId":3578544701064972,"name":"Joe0319","avatar":"https://static.tigerbbs.com/9b84d55e902f3cdc3167d94be984be1f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":3569316529855154,"repliedAuthor":{"id":3569316529855154,"idStr":"3569316529855154","authorId":3569316529855154,"name":"Deonc","avatar":"https://static.tigerbbs.com/d9aa45dd2eb58357f6477dcfb99d1415","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"objectId":867770505,"type":1,"supId":6085726,"prevId":6088026,"content":"ok","text":"ok","html":"ok"}],"langContent":"CN"},{"id":867752037,"gmtCreate":1633317347817,"gmtModify":1633317348699,"author":{"id":"3582151718585472","authorId":"3582151718585472","name":"FrederickL","avatar":"https://static.tigerbbs.com/21ae0da315b7fd514ea9d30bfa0d125a","vip":1,"crmLevel":12,"crmLevelSwitch":0,"idStr":"3582151718585472","authorIdStr":"3582151718585472"},"htmlText":"Like pls ! Thanks !","listText":"Like pls ! Thanks !","text":"Like pls ! Thanks !","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/867752037","repostId":1186540865,"repostType":4,"repost":{"id":"1186540865","kind":"news","pubTimestamp":1633289898,"share":"https://www.laohu8.com/m/news/1186540865?lang=zh_CN&edition=full","pubTime":"2021-10-04 03:38","market":"us","language":"en","title":"US IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1186540865","media":"Renaissance Capital","summary":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness co","content":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.<blockquote>在10月的第一周，由两家健身公司牵头的五起IPO预计将筹集18亿美元。</blockquote> Fitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.<blockquote>健身连锁生命时代集团控股(LTH)计划以41亿美元的市值筹集9.01亿美元。Life Time于2015年私有化，在美国29个州和加拿大一个省运营着150多个“中心”，截至2011年7月31日，为近140万个人会员提供服务。尽管该公司受到疫情的严重打击，但此后运营情况显着改善，2021年第二季度的收入翻了两番。</blockquote> Fitness equipment brandiFIT Health &amp; Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.<blockquote>健身器材品牌iFIT健康与健身(IFIT)计划以64亿美元的市值筹集6亿美元。iFIT是美国排名第一的大型健身器材供应商，销售品牌包括iFIT、NordicTrack、ProForm和Freemotion。该公司发展迅速，但尚未盈利，为120多个国家的超过610万会员和150万订户提供服务。</blockquote> Proteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.<blockquote>蛋白质组学平台等丛(ISO)计划以6.48亿美元的市值筹集1.25亿美元。IsoPlexis认为其平台是第一个同时采用蛋白质组学和单细胞生物学来表征细胞功能并将其与患者结果联系起来的平台。自2018年6月商业推出以来，该公司的平台增长迅速且利润丰厚，已被全球15大生物制药公司和美国近一半的综合癌症中心采用。</blockquote> BiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.<blockquote>生物技术忒修斯制药公司(THRX)计划以5.93亿美元的市值筹集1.25亿美元。Theseus的主要候选药物是胃肠道间质瘤(GIST)KIT激酶所有主要激活/耐药突变类别的泛变体抑制剂。该公司最近提交了高级GIST的IND，并计划在2021年第四季度晚期和2022年第一季度中部之间启动1/2期试验。</blockquote> Drug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.<blockquote>药物开发人员扣带(CING)计划以2.25亿美元的市值筹集5000万美元。其两种候选药物CTx-1301和CTx-1302正在开发用于治疗ADHD。该公司于2020年10月宣布了CTX-1301 1/2期研究的积极结果，并计划在2021年第四季度启动3期试验，预计将于2022年底获得结果。</blockquote> <img src=\"https://static.tigerbbs.com/610fa042e4de459e4597ed8086743234\" tg-width=\"1894\" tg-height=\"912\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nRenaissance Capital2021-10-04 03:38\n\n</h4>\n</header>\n<article>\nIn the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.<blockquote>在10月的第一周，由两家健身公司牵头的五起IPO预计将筹集18亿美元。</blockquote> Fitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.<blockquote>健身连锁生命时代集团控股(LTH)计划以41亿美元的市值筹集9.01亿美元。Life Time于2015年私有化，在美国29个州和加拿大一个省运营着150多个“中心”，截至2011年7月31日，为近140万个人会员提供服务。尽管该公司受到疫情的严重打击，但此后运营情况显着改善，2021年第二季度的收入翻了两番。</blockquote> Fitness equipment brandiFIT Health &amp; Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.<blockquote>健身器材品牌iFIT健康与健身(IFIT)计划以64亿美元的市值筹集6亿美元。iFIT是美国排名第一的大型健身器材供应商，销售品牌包括iFIT、NordicTrack、ProForm和Freemotion。该公司发展迅速，但尚未盈利，为120多个国家的超过610万会员和150万订户提供服务。</blockquote> Proteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.<blockquote>蛋白质组学平台等丛(ISO)计划以6.48亿美元的市值筹集1.25亿美元。IsoPlexis认为其平台是第一个同时采用蛋白质组学和单细胞生物学来表征细胞功能并将其与患者结果联系起来的平台。自2018年6月商业推出以来，该公司的平台增长迅速且利润丰厚，已被全球15大生物制药公司和美国近一半的综合癌症中心采用。</blockquote> BiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.<blockquote>生物技术忒修斯制药公司(THRX)计划以5.93亿美元的市值筹集1.25亿美元。Theseus的主要候选药物是胃肠道间质瘤(GIST)KIT激酶所有主要激活/耐药突变类别的泛变体抑制剂。该公司最近提交了高级GIST的IND，并计划在2021年第四季度晚期和2022年第一季度中部之间启动1/2期试验。</blockquote> Drug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.<blockquote>药物开发人员扣带(CING)计划以2.25亿美元的市值筹集5000万美元。其两种候选药物CTx-1301和CTx-1302正在开发用于治疗ADHD。该公司于2020年10月宣布了CTX-1301 1/2期研究的积极结果，并计划在2021年第四季度启动3期试验，预计将于2022年底获得结果。</blockquote> <img src=\"https://static.tigerbbs.com/610fa042e4de459e4597ed8086743234\" tg-width=\"1894\" tg-height=\"912\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.renaissancecapital.com/IPO-Center/News/86747/US-IPO-Week-Ahead-New-issuers-work-up-a-sweat-in-a-fitness-led-5-IPO-week\">Renaissance Capital</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ISO":"IsoPlexis Corp.","LTH":"Life Time Group Holdings, Inc.","THRX":"Theseus Pharmaceuticals, Inc.","CING":"CINGULATE INC."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/86747/US-IPO-Week-Ahead-New-issuers-work-up-a-sweat-in-a-fitness-led-5-IPO-week","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186540865","content_text":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.\nFitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.\nFitness equipment brandiFIT Health & Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.\nProteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.\nBiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.\nDrug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.","news_type":1,"symbols_score_info":{"ISO":0.9,"IFIT":0.9,"CING":0.9,"THRX":0.9,"LTH":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6085847,"gmtCreate":1633319663980,"gmtModify":1634722518181,"authorId":3580348004146675,"author":{"id":3580348004146675,"idStr":"3580348004146675","authorId":3580348004146675,"name":"sugizoi4u","avatar":"https://static.tigerbbs.com/c7f987f771f67981d200c8f1cd598c70","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":867752037,"type":1,"supId":0,"prevId":0,"content":"Done","text":"Done","html":"Done"},{"id":6093103,"gmtCreate":1633389847935,"gmtModify":1634721930460,"authorId":3567307840510045,"author":{"id":3567307840510045,"idStr":"3567307840510045","authorId":3567307840510045,"name":"JeremyKok","avatar":"https://static.tigerbbs.com/01b03a485f83b6b2615fad8ac9b87bf4","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":867752037,"type":1,"supId":0,"prevId":0,"content":"hi. please like and comment back. thank you.","text":"hi. please like and comment back. thank you.","html":"hi. please like and comment back. thank you."}],"langContent":"CN"},{"id":867756120,"gmtCreate":1633317245791,"gmtModify":1633317264359,"author":{"id":"3570772304712620","authorId":"3570772304712620","name":"jimmylaw","avatar":"https://static.tigerbbs.com/f6c847ae11f03f4682632e6fa4016040","vip":1,"crmLevel":12,"crmLevelSwitch":0,"idStr":"3570772304712620","authorIdStr":"3570772304712620"},"htmlText":"Like comment","listText":"Like comment","text":"Like comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/867756120","repostId":1186540865,"repostType":4,"repost":{"id":"1186540865","kind":"news","pubTimestamp":1633289898,"share":"https://www.laohu8.com/m/news/1186540865?lang=zh_CN&edition=full","pubTime":"2021-10-04 03:38","market":"us","language":"en","title":"US IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1186540865","media":"Renaissance Capital","summary":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness co","content":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.<blockquote>在10月的第一周，由两家健身公司牵头的五起IPO预计将筹集18亿美元。</blockquote> Fitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.<blockquote>健身连锁生命时代集团控股(LTH)计划以41亿美元的市值筹集9.01亿美元。Life Time于2015年私有化，在美国29个州和加拿大一个省运营着150多个“中心”，截至2011年7月31日，为近140万个人会员提供服务。尽管该公司受到疫情的严重打击，但此后运营情况显着改善，2021年第二季度的收入翻了两番。</blockquote> Fitness equipment brandiFIT Health &amp; Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.<blockquote>健身器材品牌iFIT健康与健身(IFIT)计划以64亿美元的市值筹集6亿美元。iFIT是美国排名第一的大型健身器材供应商，销售品牌包括iFIT、NordicTrack、ProForm和Freemotion。该公司发展迅速，但尚未盈利，为120多个国家的超过610万会员和150万订户提供服务。</blockquote> Proteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.<blockquote>蛋白质组学平台等丛(ISO)计划以6.48亿美元的市值筹集1.25亿美元。IsoPlexis认为其平台是第一个同时采用蛋白质组学和单细胞生物学来表征细胞功能并将其与患者结果联系起来的平台。自2018年6月商业推出以来，该公司的平台增长迅速且利润丰厚，已被全球15大生物制药公司和美国近一半的综合癌症中心采用。</blockquote> BiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.<blockquote>生物技术忒修斯制药公司(THRX)计划以5.93亿美元的市值筹集1.25亿美元。Theseus的主要候选药物是胃肠道间质瘤(GIST)KIT激酶所有主要激活/耐药突变类别的泛变体抑制剂。该公司最近提交了高级GIST的IND，并计划在2021年第四季度晚期和2022年第一季度中部之间启动1/2期试验。</blockquote> Drug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.<blockquote>药物开发人员扣带(CING)计划以2.25亿美元的市值筹集5000万美元。其两种候选药物CTx-1301和CTx-1302正在开发用于治疗ADHD。该公司于2020年10月宣布了CTX-1301 1/2期研究的积极结果，并计划在2021年第四季度启动3期试验，预计将于2022年底获得结果。</blockquote> <img src=\"https://static.tigerbbs.com/610fa042e4de459e4597ed8086743234\" tg-width=\"1894\" tg-height=\"912\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nRenaissance Capital2021-10-04 03:38\n\n</h4>\n</header>\n<article>\nIn the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.<blockquote>在10月的第一周，由两家健身公司牵头的五起IPO预计将筹集18亿美元。</blockquote> Fitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.<blockquote>健身连锁生命时代集团控股(LTH)计划以41亿美元的市值筹集9.01亿美元。Life Time于2015年私有化，在美国29个州和加拿大一个省运营着150多个“中心”，截至2011年7月31日，为近140万个人会员提供服务。尽管该公司受到疫情的严重打击，但此后运营情况显着改善，2021年第二季度的收入翻了两番。</blockquote> Fitness equipment brandiFIT Health &amp; Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.<blockquote>健身器材品牌iFIT健康与健身(IFIT)计划以64亿美元的市值筹集6亿美元。iFIT是美国排名第一的大型健身器材供应商，销售品牌包括iFIT、NordicTrack、ProForm和Freemotion。该公司发展迅速，但尚未盈利，为120多个国家的超过610万会员和150万订户提供服务。</blockquote> Proteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.<blockquote>蛋白质组学平台等丛(ISO)计划以6.48亿美元的市值筹集1.25亿美元。IsoPlexis认为其平台是第一个同时采用蛋白质组学和单细胞生物学来表征细胞功能并将其与患者结果联系起来的平台。自2018年6月商业推出以来，该公司的平台增长迅速且利润丰厚，已被全球15大生物制药公司和美国近一半的综合癌症中心采用。</blockquote> BiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.<blockquote>生物技术忒修斯制药公司(THRX)计划以5.93亿美元的市值筹集1.25亿美元。Theseus的主要候选药物是胃肠道间质瘤(GIST)KIT激酶所有主要激活/耐药突变类别的泛变体抑制剂。该公司最近提交了高级GIST的IND，并计划在2021年第四季度晚期和2022年第一季度中部之间启动1/2期试验。</blockquote> Drug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.<blockquote>药物开发人员扣带(CING)计划以2.25亿美元的市值筹集5000万美元。其两种候选药物CTx-1301和CTx-1302正在开发用于治疗ADHD。该公司于2020年10月宣布了CTX-1301 1/2期研究的积极结果，并计划在2021年第四季度启动3期试验，预计将于2022年底获得结果。</blockquote> <img src=\"https://static.tigerbbs.com/610fa042e4de459e4597ed8086743234\" tg-width=\"1894\" tg-height=\"912\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.renaissancecapital.com/IPO-Center/News/86747/US-IPO-Week-Ahead-New-issuers-work-up-a-sweat-in-a-fitness-led-5-IPO-week\">Renaissance Capital</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ISO":"IsoPlexis Corp.","LTH":"Life Time Group Holdings, Inc.","THRX":"Theseus Pharmaceuticals, Inc.","CING":"CINGULATE INC."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/86747/US-IPO-Week-Ahead-New-issuers-work-up-a-sweat-in-a-fitness-led-5-IPO-week","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186540865","content_text":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.\nFitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.\nFitness equipment brandiFIT Health & Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.\nProteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.\nBiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.\nDrug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.","news_type":1,"symbols_score_info":{"ISO":0.9,"IFIT":0.9,"CING":0.9,"THRX":0.9,"LTH":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6086147,"gmtCreate":1633321986638,"gmtModify":1634722492279,"authorId":3581317711527033,"author":{"id":3581317711527033,"idStr":"3581317711527033","authorId":3581317711527033,"name":"Chanelyap","avatar":"https://static.tigerbbs.com/ead5a4e57e2f9f018e7802a33c0a28f5","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":867756120,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"CN"},{"id":867756922,"gmtCreate":1633317242995,"gmtModify":1633317261694,"author":{"id":"3585269828090771","authorId":"3585269828090771","name":"CynthiaGho","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3585269828090771","authorIdStr":"3585269828090771"},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/867756922","repostId":1186540865,"repostType":4,"repost":{"id":"1186540865","kind":"news","pubTimestamp":1633289898,"share":"https://www.laohu8.com/m/news/1186540865?lang=zh_CN&edition=full","pubTime":"2021-10-04 03:38","market":"us","language":"en","title":"US IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1186540865","media":"Renaissance Capital","summary":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness co","content":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.<blockquote>在10月的第一周，由两家健身公司牵头的五起IPO预计将筹集18亿美元。</blockquote> Fitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.<blockquote>健身连锁生命时代集团控股(LTH)计划以41亿美元的市值筹集9.01亿美元。Life Time于2015年私有化，在美国29个州和加拿大一个省运营着150多个“中心”，截至2011年7月31日，为近140万个人会员提供服务。尽管该公司受到疫情的严重打击，但此后运营情况显着改善，2021年第二季度的收入翻了两番。</blockquote> Fitness equipment brandiFIT Health &amp; Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.<blockquote>健身器材品牌iFIT健康与健身(IFIT)计划以64亿美元的市值筹集6亿美元。iFIT是美国排名第一的大型健身器材供应商，销售品牌包括iFIT、NordicTrack、ProForm和Freemotion。该公司发展迅速，但尚未盈利，为120多个国家的超过610万会员和150万订户提供服务。</blockquote> Proteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.<blockquote>蛋白质组学平台等丛(ISO)计划以6.48亿美元的市值筹集1.25亿美元。IsoPlexis认为其平台是第一个同时采用蛋白质组学和单细胞生物学来表征细胞功能并将其与患者结果联系起来的平台。自2018年6月商业推出以来，该公司的平台增长迅速且利润丰厚，已被全球15大生物制药公司和美国近一半的综合癌症中心采用。</blockquote> BiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.<blockquote>生物技术忒修斯制药公司(THRX)计划以5.93亿美元的市值筹集1.25亿美元。Theseus的主要候选药物是胃肠道间质瘤(GIST)KIT激酶所有主要激活/耐药突变类别的泛变体抑制剂。该公司最近提交了高级GIST的IND，并计划在2021年第四季度晚期和2022年第一季度中部之间启动1/2期试验。</blockquote> Drug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.<blockquote>药物开发人员扣带(CING)计划以2.25亿美元的市值筹集5000万美元。其两种候选药物CTx-1301和CTx-1302正在开发用于治疗ADHD。该公司于2020年10月宣布了CTX-1301 1/2期研究的积极结果，并计划在2021年第四季度启动3期试验，预计将于2022年底获得结果。</blockquote> <img src=\"https://static.tigerbbs.com/610fa042e4de459e4597ed8086743234\" tg-width=\"1894\" tg-height=\"912\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nRenaissance Capital2021-10-04 03:38\n\n</h4>\n</header>\n<article>\nIn the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.<blockquote>在10月的第一周，由两家健身公司牵头的五起IPO预计将筹集18亿美元。</blockquote> Fitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.<blockquote>健身连锁生命时代集团控股(LTH)计划以41亿美元的市值筹集9.01亿美元。Life Time于2015年私有化，在美国29个州和加拿大一个省运营着150多个“中心”，截至2011年7月31日，为近140万个人会员提供服务。尽管该公司受到疫情的严重打击，但此后运营情况显着改善，2021年第二季度的收入翻了两番。</blockquote> Fitness equipment brandiFIT Health &amp; Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.<blockquote>健身器材品牌iFIT健康与健身(IFIT)计划以64亿美元的市值筹集6亿美元。iFIT是美国排名第一的大型健身器材供应商，销售品牌包括iFIT、NordicTrack、ProForm和Freemotion。该公司发展迅速，但尚未盈利，为120多个国家的超过610万会员和150万订户提供服务。</blockquote> Proteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.<blockquote>蛋白质组学平台等丛(ISO)计划以6.48亿美元的市值筹集1.25亿美元。IsoPlexis认为其平台是第一个同时采用蛋白质组学和单细胞生物学来表征细胞功能并将其与患者结果联系起来的平台。自2018年6月商业推出以来，该公司的平台增长迅速且利润丰厚，已被全球15大生物制药公司和美国近一半的综合癌症中心采用。</blockquote> BiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.<blockquote>生物技术忒修斯制药公司(THRX)计划以5.93亿美元的市值筹集1.25亿美元。Theseus的主要候选药物是胃肠道间质瘤(GIST)KIT激酶所有主要激活/耐药突变类别的泛变体抑制剂。该公司最近提交了高级GIST的IND，并计划在2021年第四季度晚期和2022年第一季度中部之间启动1/2期试验。</blockquote> Drug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.<blockquote>药物开发人员扣带(CING)计划以2.25亿美元的市值筹集5000万美元。其两种候选药物CTx-1301和CTx-1302正在开发用于治疗ADHD。该公司于2020年10月宣布了CTX-1301 1/2期研究的积极结果，并计划在2021年第四季度启动3期试验，预计将于2022年底获得结果。</blockquote> <img src=\"https://static.tigerbbs.com/610fa042e4de459e4597ed8086743234\" tg-width=\"1894\" tg-height=\"912\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.renaissancecapital.com/IPO-Center/News/86747/US-IPO-Week-Ahead-New-issuers-work-up-a-sweat-in-a-fitness-led-5-IPO-week\">Renaissance Capital</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ISO":"IsoPlexis Corp.","LTH":"Life Time Group Holdings, Inc.","THRX":"Theseus Pharmaceuticals, Inc.","CING":"CINGULATE INC."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/86747/US-IPO-Week-Ahead-New-issuers-work-up-a-sweat-in-a-fitness-led-5-IPO-week","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186540865","content_text":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.\nFitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.\nFitness equipment brandiFIT Health & Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.\nProteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.\nBiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.\nDrug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.","news_type":1,"symbols_score_info":{"ISO":0.9,"IFIT":0.9,"CING":0.9,"THRX":0.9,"LTH":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6085482,"gmtCreate":1633317252606,"gmtModify":1634722546458,"authorId":3570772304712620,"author":{"id":3570772304712620,"idStr":"3570772304712620","authorId":3570772304712620,"name":"jimmylaw","avatar":"https://static.tigerbbs.com/f6c847ae11f03f4682632e6fa4016040","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":867756922,"type":1,"supId":0,"prevId":0,"content":"comment like","text":"comment like","html":"comment like"},{"id":6093107,"gmtCreate":1633389854831,"gmtModify":1634721930025,"authorId":3567307840510045,"author":{"id":3567307840510045,"idStr":"3567307840510045","authorId":3567307840510045,"name":"JeremyKok","avatar":"https://static.tigerbbs.com/01b03a485f83b6b2615fad8ac9b87bf4","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":867756922,"type":1,"supId":0,"prevId":0,"content":"hi. please like and comment back. thank you.","text":"hi. please like and comment back. thank you.","html":"hi. please like and comment back. thank you."}],"langContent":"CN"},{"id":867750308,"gmtCreate":1633316943937,"gmtModify":1633316944417,"author":{"id":"3582065904370135","authorId":"3582065904370135","name":"OddEyeCircle","avatar":"https://static.tigerbbs.com/bd89742cea79ac97ec7da1a7bdbc2a14","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3582065904370135","authorIdStr":"3582065904370135"},"htmlText":"Please like and comment","listText":"Please like and comment","text":"Please like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/867750308","repostId":1186540865,"repostType":4,"repost":{"id":"1186540865","kind":"news","pubTimestamp":1633289898,"share":"https://www.laohu8.com/m/news/1186540865?lang=zh_CN&edition=full","pubTime":"2021-10-04 03:38","market":"us","language":"en","title":"US IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1186540865","media":"Renaissance Capital","summary":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness co","content":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.<blockquote>在10月的第一周，由两家健身公司牵头的五起IPO预计将筹集18亿美元。</blockquote> Fitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.<blockquote>健身连锁生命时代集团控股(LTH)计划以41亿美元的市值筹集9.01亿美元。Life Time于2015年私有化，在美国29个州和加拿大一个省运营着150多个“中心”，截至2011年7月31日，为近140万个人会员提供服务。尽管该公司受到疫情的严重打击，但此后运营情况显着改善，2021年第二季度的收入翻了两番。</blockquote> Fitness equipment brandiFIT Health &amp; Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.<blockquote>健身器材品牌iFIT健康与健身(IFIT)计划以64亿美元的市值筹集6亿美元。iFIT是美国排名第一的大型健身器材供应商，销售品牌包括iFIT、NordicTrack、ProForm和Freemotion。该公司发展迅速，但尚未盈利，为120多个国家的超过610万会员和150万订户提供服务。</blockquote> Proteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.<blockquote>蛋白质组学平台等丛(ISO)计划以6.48亿美元的市值筹集1.25亿美元。IsoPlexis认为其平台是第一个同时采用蛋白质组学和单细胞生物学来表征细胞功能并将其与患者结果联系起来的平台。自2018年6月商业推出以来，该公司的平台增长迅速且利润丰厚，已被全球15大生物制药公司和美国近一半的综合癌症中心采用。</blockquote> BiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.<blockquote>生物技术忒修斯制药公司(THRX)计划以5.93亿美元的市值筹集1.25亿美元。Theseus的主要候选药物是胃肠道间质瘤(GIST)KIT激酶所有主要激活/耐药突变类别的泛变体抑制剂。该公司最近提交了高级GIST的IND，并计划在2021年第四季度晚期和2022年第一季度中部之间启动1/2期试验。</blockquote> Drug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.<blockquote>药物开发人员扣带(CING)计划以2.25亿美元的市值筹集5000万美元。其两种候选药物CTx-1301和CTx-1302正在开发用于治疗ADHD。该公司于2020年10月宣布了CTX-1301 1/2期研究的积极结果，并计划在2021年第四季度启动3期试验，预计将于2022年底获得结果。</blockquote> <img src=\"https://static.tigerbbs.com/610fa042e4de459e4597ed8086743234\" tg-width=\"1894\" tg-height=\"912\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nRenaissance Capital2021-10-04 03:38\n\n</h4>\n</header>\n<article>\nIn the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.<blockquote>在10月的第一周，由两家健身公司牵头的五起IPO预计将筹集18亿美元。</blockquote> Fitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.<blockquote>健身连锁生命时代集团控股(LTH)计划以41亿美元的市值筹集9.01亿美元。Life Time于2015年私有化，在美国29个州和加拿大一个省运营着150多个“中心”，截至2011年7月31日，为近140万个人会员提供服务。尽管该公司受到疫情的严重打击，但此后运营情况显着改善，2021年第二季度的收入翻了两番。</blockquote> Fitness equipment brandiFIT Health &amp; Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.<blockquote>健身器材品牌iFIT健康与健身(IFIT)计划以64亿美元的市值筹集6亿美元。iFIT是美国排名第一的大型健身器材供应商，销售品牌包括iFIT、NordicTrack、ProForm和Freemotion。该公司发展迅速，但尚未盈利，为120多个国家的超过610万会员和150万订户提供服务。</blockquote> Proteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.<blockquote>蛋白质组学平台等丛(ISO)计划以6.48亿美元的市值筹集1.25亿美元。IsoPlexis认为其平台是第一个同时采用蛋白质组学和单细胞生物学来表征细胞功能并将其与患者结果联系起来的平台。自2018年6月商业推出以来，该公司的平台增长迅速且利润丰厚，已被全球15大生物制药公司和美国近一半的综合癌症中心采用。</blockquote> BiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.<blockquote>生物技术忒修斯制药公司(THRX)计划以5.93亿美元的市值筹集1.25亿美元。Theseus的主要候选药物是胃肠道间质瘤(GIST)KIT激酶所有主要激活/耐药突变类别的泛变体抑制剂。该公司最近提交了高级GIST的IND，并计划在2021年第四季度晚期和2022年第一季度中部之间启动1/2期试验。</blockquote> Drug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.<blockquote>药物开发人员扣带(CING)计划以2.25亿美元的市值筹集5000万美元。其两种候选药物CTx-1301和CTx-1302正在开发用于治疗ADHD。该公司于2020年10月宣布了CTX-1301 1/2期研究的积极结果，并计划在2021年第四季度启动3期试验，预计将于2022年底获得结果。</blockquote> <img src=\"https://static.tigerbbs.com/610fa042e4de459e4597ed8086743234\" tg-width=\"1894\" tg-height=\"912\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.renaissancecapital.com/IPO-Center/News/86747/US-IPO-Week-Ahead-New-issuers-work-up-a-sweat-in-a-fitness-led-5-IPO-week\">Renaissance Capital</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ISO":"IsoPlexis Corp.","LTH":"Life Time Group Holdings, Inc.","THRX":"Theseus Pharmaceuticals, Inc.","CING":"CINGULATE INC."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/86747/US-IPO-Week-Ahead-New-issuers-work-up-a-sweat-in-a-fitness-led-5-IPO-week","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186540865","content_text":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.\nFitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.\nFitness equipment brandiFIT Health & Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.\nProteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.\nBiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.\nDrug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.","news_type":1,"symbols_score_info":{"ISO":0.9,"IFIT":0.9,"CING":0.9,"THRX":0.9,"LTH":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6085477,"gmtCreate":1633317234737,"gmtModify":1634722546674,"authorId":3585269828090771,"author":{"id":3585269828090771,"idStr":"3585269828090771","authorId":3585269828090771,"name":"CynthiaGho","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":867750308,"type":1,"supId":0,"prevId":0,"content":"👍","text":"👍","html":"👍"},{"id":6093110,"gmtCreate":1633389861159,"gmtModify":1634721929699,"authorId":3567307840510045,"author":{"id":3567307840510045,"idStr":"3567307840510045","authorId":3567307840510045,"name":"JeremyKok","avatar":"https://static.tigerbbs.com/01b03a485f83b6b2615fad8ac9b87bf4","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":867750308,"type":1,"supId":0,"prevId":0,"content":"hi. please like and comment back. thank you.","text":"hi. please like and comment back. thank you.","html":"hi. please like and comment back. thank you."}],"langContent":"CN"},{"id":867760213,"gmtCreate":1633314919610,"gmtModify":1633314920316,"author":{"id":"3584955097359320","authorId":"3584955097359320","name":"FlareSpark","avatar":"https://static.tigerbbs.com/38942f5d417a8d645800903b08402b4e","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3584955097359320","authorIdStr":"3584955097359320"},"htmlText":"New opportunities&nbsp;","listText":"New opportunities&nbsp;","text":"New opportunities","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/867760213","repostId":1186540865,"repostType":4,"repost":{"id":"1186540865","kind":"news","pubTimestamp":1633289898,"share":"https://www.laohu8.com/m/news/1186540865?lang=zh_CN&edition=full","pubTime":"2021-10-04 03:38","market":"us","language":"en","title":"US IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1186540865","media":"Renaissance Capital","summary":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness co","content":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.<blockquote>在10月的第一周，由两家健身公司牵头的五起IPO预计将筹集18亿美元。</blockquote> Fitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.<blockquote>健身连锁生命时代集团控股(LTH)计划以41亿美元的市值筹集9.01亿美元。Life Time于2015年私有化，在美国29个州和加拿大一个省运营着150多个“中心”，截至2011年7月31日，为近140万个人会员提供服务。尽管该公司受到疫情的严重打击，但此后运营情况显着改善，2021年第二季度的收入翻了两番。</blockquote> Fitness equipment brandiFIT Health &amp; Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.<blockquote>健身器材品牌iFIT健康与健身(IFIT)计划以64亿美元的市值筹集6亿美元。iFIT是美国排名第一的大型健身器材供应商，销售品牌包括iFIT、NordicTrack、ProForm和Freemotion。该公司发展迅速，但尚未盈利，为120多个国家的超过610万会员和150万订户提供服务。</blockquote> Proteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.<blockquote>蛋白质组学平台等丛(ISO)计划以6.48亿美元的市值筹集1.25亿美元。IsoPlexis认为其平台是第一个同时采用蛋白质组学和单细胞生物学来表征细胞功能并将其与患者结果联系起来的平台。自2018年6月商业推出以来，该公司的平台增长迅速且利润丰厚，已被全球15大生物制药公司和美国近一半的综合癌症中心采用。</blockquote> BiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.<blockquote>生物技术忒修斯制药公司(THRX)计划以5.93亿美元的市值筹集1.25亿美元。Theseus的主要候选药物是胃肠道间质瘤(GIST)KIT激酶所有主要激活/耐药突变类别的泛变体抑制剂。该公司最近提交了高级GIST的IND，并计划在2021年第四季度晚期和2022年第一季度中部之间启动1/2期试验。</blockquote> Drug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.<blockquote>药物开发人员扣带(CING)计划以2.25亿美元的市值筹集5000万美元。其两种候选药物CTx-1301和CTx-1302正在开发用于治疗ADHD。该公司于2020年10月宣布了CTX-1301 1/2期研究的积极结果，并计划在2021年第四季度启动3期试验，预计将于2022年底获得结果。</blockquote> <img src=\"https://static.tigerbbs.com/610fa042e4de459e4597ed8086743234\" tg-width=\"1894\" tg-height=\"912\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nRenaissance Capital2021-10-04 03:38\n\n</h4>\n</header>\n<article>\nIn the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.<blockquote>在10月的第一周，由两家健身公司牵头的五起IPO预计将筹集18亿美元。</blockquote> Fitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.<blockquote>健身连锁生命时代集团控股(LTH)计划以41亿美元的市值筹集9.01亿美元。Life Time于2015年私有化，在美国29个州和加拿大一个省运营着150多个“中心”，截至2011年7月31日，为近140万个人会员提供服务。尽管该公司受到疫情的严重打击，但此后运营情况显着改善，2021年第二季度的收入翻了两番。</blockquote> Fitness equipment brandiFIT Health &amp; Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.<blockquote>健身器材品牌iFIT健康与健身(IFIT)计划以64亿美元的市值筹集6亿美元。iFIT是美国排名第一的大型健身器材供应商，销售品牌包括iFIT、NordicTrack、ProForm和Freemotion。该公司发展迅速，但尚未盈利，为120多个国家的超过610万会员和150万订户提供服务。</blockquote> Proteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.<blockquote>蛋白质组学平台等丛(ISO)计划以6.48亿美元的市值筹集1.25亿美元。IsoPlexis认为其平台是第一个同时采用蛋白质组学和单细胞生物学来表征细胞功能并将其与患者结果联系起来的平台。自2018年6月商业推出以来，该公司的平台增长迅速且利润丰厚，已被全球15大生物制药公司和美国近一半的综合癌症中心采用。</blockquote> BiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.<blockquote>生物技术忒修斯制药公司(THRX)计划以5.93亿美元的市值筹集1.25亿美元。Theseus的主要候选药物是胃肠道间质瘤(GIST)KIT激酶所有主要激活/耐药突变类别的泛变体抑制剂。该公司最近提交了高级GIST的IND，并计划在2021年第四季度晚期和2022年第一季度中部之间启动1/2期试验。</blockquote> Drug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.<blockquote>药物开发人员扣带(CING)计划以2.25亿美元的市值筹集5000万美元。其两种候选药物CTx-1301和CTx-1302正在开发用于治疗ADHD。该公司于2020年10月宣布了CTX-1301 1/2期研究的积极结果，并计划在2021年第四季度启动3期试验，预计将于2022年底获得结果。</blockquote> <img src=\"https://static.tigerbbs.com/610fa042e4de459e4597ed8086743234\" tg-width=\"1894\" tg-height=\"912\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.renaissancecapital.com/IPO-Center/News/86747/US-IPO-Week-Ahead-New-issuers-work-up-a-sweat-in-a-fitness-led-5-IPO-week\">Renaissance Capital</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ISO":"IsoPlexis Corp.","LTH":"Life Time Group Holdings, Inc.","THRX":"Theseus Pharmaceuticals, Inc.","CING":"CINGULATE INC."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/86747/US-IPO-Week-Ahead-New-issuers-work-up-a-sweat-in-a-fitness-led-5-IPO-week","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186540865","content_text":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.\nFitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.\nFitness equipment brandiFIT Health & Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.\nProteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.\nBiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.\nDrug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.","news_type":1,"symbols_score_info":{"ISO":0.9,"IFIT":0.9,"CING":0.9,"THRX":0.9,"LTH":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6085249,"gmtCreate":1633316156335,"gmtModify":1634722563341,"authorId":3582787876379103,"author":{"id":3582787876379103,"idStr":"3582787876379103","authorId":3582787876379103,"name":"p3aceboi","avatar":"https://static.tigerbbs.com/a7a9f78be43ebaac2aa101e08ea4832d","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":867760213,"type":1,"supId":0,"prevId":0,"content":"[Miser]","text":"[Miser]","html":"[Miser]"},{"id":6085417,"gmtCreate":1633316954661,"gmtModify":1634722550804,"authorId":3582065904370135,"author":{"id":3582065904370135,"idStr":"3582065904370135","authorId":3582065904370135,"name":"OddEyeCircle","avatar":"https://static.tigerbbs.com/bd89742cea79ac97ec7da1a7bdbc2a14","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":867760213,"type":1,"supId":0,"prevId":0,"content":"please like and comment","text":"please like and comment","html":"please like and comment"}],"langContent":"CN"},{"id":867786899,"gmtCreate":1633314524672,"gmtModify":1633314524962,"author":{"id":"3582942911161794","authorId":"3582942911161794","name":"Nanamoney","avatar":"https://static.tigerbbs.com/8624e691b889b8bc4515d1884744eb5a","vip":1,"crmLevel":12,"crmLevelSwitch":0,"idStr":"3582942911161794","authorIdStr":"3582942911161794"},"htmlText":"This can be interesting. Thanks","listText":"This can be interesting. Thanks","text":"This can be interesting. Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/867786899","repostId":1186540865,"repostType":4,"repost":{"id":"1186540865","kind":"news","pubTimestamp":1633289898,"share":"https://www.laohu8.com/m/news/1186540865?lang=zh_CN&edition=full","pubTime":"2021-10-04 03:38","market":"us","language":"en","title":"US IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1186540865","media":"Renaissance Capital","summary":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness co","content":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.<blockquote>在10月的第一周，由两家健身公司牵头的五起IPO预计将筹集18亿美元。</blockquote> Fitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.<blockquote>健身连锁生命时代集团控股(LTH)计划以41亿美元的市值筹集9.01亿美元。Life Time于2015年私有化，在美国29个州和加拿大一个省运营着150多个“中心”，截至2011年7月31日，为近140万个人会员提供服务。尽管该公司受到疫情的严重打击，但此后运营情况显着改善，2021年第二季度的收入翻了两番。</blockquote> Fitness equipment brandiFIT Health &amp; Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.<blockquote>健身器材品牌iFIT健康与健身(IFIT)计划以64亿美元的市值筹集6亿美元。iFIT是美国排名第一的大型健身器材供应商，销售品牌包括iFIT、NordicTrack、ProForm和Freemotion。该公司发展迅速，但尚未盈利，为120多个国家的超过610万会员和150万订户提供服务。</blockquote> Proteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.<blockquote>蛋白质组学平台等丛(ISO)计划以6.48亿美元的市值筹集1.25亿美元。IsoPlexis认为其平台是第一个同时采用蛋白质组学和单细胞生物学来表征细胞功能并将其与患者结果联系起来的平台。自2018年6月商业推出以来，该公司的平台增长迅速且利润丰厚，已被全球15大生物制药公司和美国近一半的综合癌症中心采用。</blockquote> BiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.<blockquote>生物技术忒修斯制药公司(THRX)计划以5.93亿美元的市值筹集1.25亿美元。Theseus的主要候选药物是胃肠道间质瘤(GIST)KIT激酶所有主要激活/耐药突变类别的泛变体抑制剂。该公司最近提交了高级GIST的IND，并计划在2021年第四季度晚期和2022年第一季度中部之间启动1/2期试验。</blockquote> Drug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.<blockquote>药物开发人员扣带(CING)计划以2.25亿美元的市值筹集5000万美元。其两种候选药物CTx-1301和CTx-1302正在开发用于治疗ADHD。该公司于2020年10月宣布了CTX-1301 1/2期研究的积极结果，并计划在2021年第四季度启动3期试验，预计将于2022年底获得结果。</blockquote> <img src=\"https://static.tigerbbs.com/610fa042e4de459e4597ed8086743234\" tg-width=\"1894\" tg-height=\"912\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Week Ahead: New issuers work up a sweat in a fitness-led 5 IPO week<blockquote>美国IPO一周即将到来：新发行人在健身主导的5周IPO中大汗淋漓</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nRenaissance Capital2021-10-04 03:38\n\n</h4>\n</header>\n<article>\nIn the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.<blockquote>在10月的第一周，由两家健身公司牵头的五起IPO预计将筹集18亿美元。</blockquote> Fitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.<blockquote>健身连锁生命时代集团控股(LTH)计划以41亿美元的市值筹集9.01亿美元。Life Time于2015年私有化，在美国29个州和加拿大一个省运营着150多个“中心”，截至2011年7月31日，为近140万个人会员提供服务。尽管该公司受到疫情的严重打击，但此后运营情况显着改善，2021年第二季度的收入翻了两番。</blockquote> Fitness equipment brandiFIT Health &amp; Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.<blockquote>健身器材品牌iFIT健康与健身(IFIT)计划以64亿美元的市值筹集6亿美元。iFIT是美国排名第一的大型健身器材供应商，销售品牌包括iFIT、NordicTrack、ProForm和Freemotion。该公司发展迅速，但尚未盈利，为120多个国家的超过610万会员和150万订户提供服务。</blockquote> Proteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.<blockquote>蛋白质组学平台等丛(ISO)计划以6.48亿美元的市值筹集1.25亿美元。IsoPlexis认为其平台是第一个同时采用蛋白质组学和单细胞生物学来表征细胞功能并将其与患者结果联系起来的平台。自2018年6月商业推出以来，该公司的平台增长迅速且利润丰厚，已被全球15大生物制药公司和美国近一半的综合癌症中心采用。</blockquote> BiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.<blockquote>生物技术忒修斯制药公司(THRX)计划以5.93亿美元的市值筹集1.25亿美元。Theseus的主要候选药物是胃肠道间质瘤(GIST)KIT激酶所有主要激活/耐药突变类别的泛变体抑制剂。该公司最近提交了高级GIST的IND，并计划在2021年第四季度晚期和2022年第一季度中部之间启动1/2期试验。</blockquote> Drug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.<blockquote>药物开发人员扣带(CING)计划以2.25亿美元的市值筹集5000万美元。其两种候选药物CTx-1301和CTx-1302正在开发用于治疗ADHD。该公司于2020年10月宣布了CTX-1301 1/2期研究的积极结果，并计划在2021年第四季度启动3期试验，预计将于2022年底获得结果。</blockquote> <img src=\"https://static.tigerbbs.com/610fa042e4de459e4597ed8086743234\" tg-width=\"1894\" tg-height=\"912\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.renaissancecapital.com/IPO-Center/News/86747/US-IPO-Week-Ahead-New-issuers-work-up-a-sweat-in-a-fitness-led-5-IPO-week\">Renaissance Capital</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ISO":"IsoPlexis Corp.","LTH":"Life Time Group Holdings, Inc.","THRX":"Theseus Pharmaceuticals, Inc.","CING":"CINGULATE INC."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/86747/US-IPO-Week-Ahead-New-issuers-work-up-a-sweat-in-a-fitness-led-5-IPO-week","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186540865","content_text":"In the first full week of October, five IPOs are slated to raise $1.8 billion, led by two fitness companies.\nFitness chainLife Time Group Holdings(LTH) plans to raise $901 million at a $4.1 billion market cap. Taken private in 2015, Life Time operates more than 150 \"centers\" across 29 US states and one province in Canada, serving nearly 1.4 million individual members as of 7/31/21. While the company was hit hard by the pandemic, operations have since improved dramatically, with revenue quadrupling in the 2Q21.\nFitness equipment brandiFIT Health & Fitness(IFIT) plans to raise $600 million at a $6.4 billion market cap. iFIT is the #1 provider of large fitness equipment in the US, selling under brands including iFIT, NordicTrack, ProForm, and Freemotion. Fast growing and unprofitable, the company serves a community of over 6.1 million members and 1.5 million subscribers in over 120 countries.\nProteomics platformIsoPlexis(ISO) plans to raise $125 million at a $648 million market cap. IsoPlexis believes its platform is the first to employ both proteomics and single cell biology to characterize and link cellular function to patient outcomes. Fast growing and highly unprofitable, the company's platform has been adopted by the top 15 global biopharmas and nearly half of the comprehensive cancer centers in the US since its commercial launch in June 2018.\nBiotechTheseus Pharmaceuticals(THRX) plans to raise $125 million at a $593 million market cap. Theseus’ lead candidate is a pan-variant inhibitor of all major classes of activating/resistance mutations of the KIT kinase for of gastrointestinal stromal tumors (GIST). The company recently submitted an IND for advanced GIST and plans to initiate a Phase 1/2 trial between late 4Q21 and mid 1Q22.\nDrug developerCingulate(CING) plans to raise $50 million at a $225 million market cap. Its two candidates, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD. The company announced positive results from a Phase 1/2 study of CTx-1301 in October 2020, and plans to initiate Phase 3 trials in the 4Q21 with results expected in late 2022.","news_type":1,"symbols_score_info":{"ISO":0.9,"IFIT":0.9,"CING":0.9,"THRX":0.9,"LTH":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":971,"commentSize":71,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}